<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neurology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32670191</article-id>
<article-id pub-id-type="pmc">7330114</article-id>
<article-id pub-id-type="doi">10.3389/fneur.2020.00598</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gut Microbiota in Acute Ischemic Stroke: From Pathophysiology to Therapeutic Implications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Battaglini</surname>
<given-names>Denise</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/990025/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pimentel-Coelho</surname>
<given-names>Pedro Moreno</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/201407/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robba</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/663913/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>dos Santos</surname>
<given-names>Claudia C.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cruz</surname>
<given-names>Fernanda Ferreira</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/985281/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pelosi</surname>
<given-names>Paolo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/803249/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rocco</surname>
<given-names>Patricia Rieken Macedo</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/175776/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Surgical Sciences and Integrated Diagnostics, University of Genoa</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff>
<aff id="aff3"><sup>3</sup><institution>Laboratório de Neurobiologia Comparada e do Desenvolvimento, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country></aff>
<aff id="aff4"><sup>4</sup><institution>Keenan and Li Ka Shing Knowledge Institute, University Health Toronto—St. Michael's Hospital</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country></aff>
<aff id="aff5"><sup>5</sup><institution>Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country></aff>
<aff id="aff6"><sup>6</sup><institution>Rio de Janeiro Network on Neuroinflammation, Carlos Chagas Filho Foundation for Supporting Research in the State of Rio de Janeiro (FAPERJ)</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Johannes Boltze, University of Warwick, United Kingdom</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Javier Ochoa-Reparaz, Eastern Washington University, United States; Yan He, Southern Medical University, China; Jia Yin, Southern Medical University, China</p>
</fn>
<corresp id="c001">*Correspondence: Patricia Rieken Macedo Rocco <email>prmrocco@biof.ufrj.br</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Stroke, a section of the journal Frontiers in Neurology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>598</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>3</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Battaglini, Pimentel-Coelho, Robba, dos Santos, Cruz, Pelosi and Rocco.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Battaglini, Pimentel-Coelho, Robba, dos Santos, Cruz, Pelosi and Rocco</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>The microbiota–gut–brain axis is considered a central regulator of the immune system after acute ischemic stroke (AIS), with a potential role in determining outcome. Several pathways are involved in the evolution of gut microbiota dysbiosis after AIS. <italic>Brain–gut</italic> and <italic>gut–brain</italic> signaling pathways involve bidirectional communication between the hypothalamic–pituitary–adrenal axis, the autonomic nervous system, the enteric nervous system, and the immune cells of the gut. Alterations in gut microbiome can be a risk factor and may also lead to AIS. Both risk factors for AIS and gut-microbiome composition are influenced by similar factors, including diabetes, hypertension, hyperlipidemia, obesity, and vascular dysfunction. Furthermore, the systemic inflammatory response after AIS may yield liver, renal, respiratory, gastrointestinal, and cardiovascular impairment, including the multiple organ dysfunction syndrome. This review focus on biochemical, immunological, and neuroanatomical modulation of gut microbiota and its possible systemic harmful effects after AIS, as well as the role of ischemic stroke on microbiota composition. Finally, we highlight the role of gut microbiota as a potential novel therapeutic target in acute ischemic stroke.</p>
</abstract>
<kwd-group>
<kwd>microbiome</kwd>
<kwd>acute ischemic stroke</kwd>
<kwd>inflammation</kwd>
<kwd>dysbiosis</kwd>
<kwd>microbiota</kwd>
</kwd-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="129"></ref-count>
<page-count count="13"></page-count>
<word-count count="9878"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Acute ischemic stroke (AIS) is the second leading cause of death worldwide, accounting for up to 25% of global lifetime risk (<xref ref-type="bibr" rid="B1">1</xref>). Great effort has been invested into identifying risk factors, elucidating pathogenesis, and discovering implications for outcomes (<xref ref-type="bibr" rid="B2">2</xref>). Post-AIS infection has been identified as a key cause of death and prolonged hospitalization after stroke (<xref ref-type="bibr" rid="B3">3</xref>). Recent advances have demonstrated, for instance, that peripheral adaptive immunity is activated and recruited into the brain within the first few hours/days after AIS (<xref ref-type="bibr" rid="B4">4</xref>), and that its cells might regulate and be regulated by the gut microbiota (<xref ref-type="bibr" rid="B5">5</xref>). A microbiota is defined as an ecological unit composed of microorganisms within a specific (micro) environment, while the microbiome is the genetic material of these microorganisms (<xref ref-type="bibr" rid="B6">6</xref>). Dysbiosis is defined as a microbial imbalance in composition and function of the microbiota, occurring in several animal models of AIS which demonstrates that gut microbiota can regulate the neuroinflammatory response, influencing brain recovery (<xref ref-type="bibr" rid="B7">7</xref>). Several studies have focused on the relationship between the intestinal microbiome and AIS, confirming the existence of a bidirectional microbiota–gut–brain axis (<xref ref-type="bibr" rid="B8">8</xref>). In fact, alterations in gut microbiome can be a risk factor for AIS, and vice-versa; AIS may lead to changes in gut microbiome, impacting on peripheral organs and leading to severe liver, renal, respiratory, gastrointestinal and cardiovascular impairment, including the multiple organ dysfunction syndrome (MODS) (<xref ref-type="bibr" rid="B9">9</xref>). The aim of this review is to highlight the pathophysiology potentially involved in gut microbiota modulation after AIS, and its implication for therapy and outcome.</p>
</sec>
<sec id="s2">
<title>Pathophysiology</title>
<sec>
<title>Brain–Gut–Microbiota Axis</title>
<sec>
<title>Communication Pathways</title>
<p>Recent evidence confirms the existence of bidirectional communication pathways linking the brain and the gut. The pathways involved in brain-gut axis include sympathetic and parasympathetic activation, the hypothalamic–pituitary–adrenal axis, and the immune system at a central level (<xref ref-type="bibr" rid="B8">8</xref>). The hypothalamic–pituitary–adrenal axis is a key communication mechanism between the brain and gut, particularly in response to a variety of stressful and stimuli (<xref ref-type="bibr" rid="B10">10</xref>). The autonomic nervous system, after integrating neuronal and neuroendocrine signaling, modulates intestinal homeostasis, thus enhancing inflammation in gut tissue, reducing the number of goblet cells in the cecum, and impairing mucin production in the overall intestine (<xref ref-type="bibr" rid="B8">8</xref>). The autonomic system is further responsible for controlling gut motility, permeability, fluid maintenance, bile secretion, bicarbonate and mucus production, intestinal fluid handling, and the mucosal neuroimmune response (<xref ref-type="bibr" rid="B11">11</xref>). Peripheral connections from the gut to the brain consist of the enteric and autonomic nervous systems, alongside the autonomic nervous system and various neuroimmune and neuroendocrine pathways (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B8">8</xref>). These include serotonin, gamma-amino butyric acid (GABA), catecholamines (<xref ref-type="bibr" rid="B12">12</xref>), cholecystokinin, glucagon-like peptide-1, and neuropeptide Y (<xref ref-type="bibr" rid="B7">7</xref>). Bottom-up signals triggered upon stimulation of hepatic and celiac branches of the <italic>vagus</italic> nerve by microbial compounds, metabolites, and hormones released from the gut are carried by afferent vagal branches to the brain (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Bottom-up and top-down signaling in stroke. Bottom-up signaling from the gut to the brain includes barrier integrity maintenance, immune response (e.g., immunoglobulin A secretion), neurotransmitter and neuropeptide release, short-chain fatty acid (e.g., butyrate) release, and vagus nerve activation. Top-down signaling includes release of neurotransmitters (e.g., dopamine, serotonin), stress response (e.g., cortisol release), mucus secretion, and peristalsis control. [SCFA, short chain fatty acid; DA, dopamine; 5HT, serotonin; Ig, immunoglobulin, PYY, peptide YY; GLP-1, glucagon-like peptide-1; CKK, cholecystokinin; GABA, gamma amino butyric acid].</p>
</caption>
<graphic xlink:href="fneur-11-00598-g0001"></graphic>
</fig>
</sec>
</sec>
<sec>
<title>Gut Dysbiosis and Neurological Disorders</title>
<p>Molecular biology has made great strides in characterizing which microorganisms co-inhabit each host and how this community may change over time. Each individual shows a unique microbiota profile with specific functions, such as immunomodulation, protection against pathogens, maintenance of gut mucosal barrier integrity, and control of nutrient metabolism (<xref ref-type="bibr" rid="B14">14</xref>). The largest population of commensal bacteria, comprising more than 1,000 species, is located in the digestive tract (<xref ref-type="bibr" rid="B15">15</xref>). Mucosal bacteria are more interactive with host cells when compared to luminal bacteria, influencing host gene expression and healing (<xref ref-type="bibr" rid="B16">16</xref>). This occurs, in part, due to the presence of the intestinal mucus layer, an essential component of the protective barrier between the intestinal epithelium and the gut lumen (<xref ref-type="bibr" rid="B17">17</xref>). The gut microbiota is composed of several bacterial species, of which 90% is represented by <italic>Firmicutes</italic> and <italic>Bacteroidetes</italic>. The <italic>Firmicutes</italic> phylum is predominantly composed of clostridial genera (<xref ref-type="bibr" rid="B14">14</xref>). Dysbiosis is usually caused by several mechanisms, such as infection, inflammation, diet, xenobiotics, and genetics, although the full list of lifestyle factors involved in microbiota modulation is still unknown (<xref ref-type="bibr" rid="B18">18</xref>). Inflammation compromises the microbiotic defense against pathogens causing dysbiosis, since the innate and adaptive immune systems are essential in regulation of microbiota homeostasis (<xref ref-type="bibr" rid="B19">19</xref>). The enteric nervous system is composed of the submucosal and the myenteric plexuses, which control intestinal motility and fluid movement (<xref ref-type="bibr" rid="B20">20</xref>). Their function is influenced by the activation of pattern recognition receptors (PRRs), especially toll-like receptors (TLRs) (<xref ref-type="bibr" rid="B21">21</xref>). Innate immunity primarily recognizes gut microbes by pathogen-associated molecular patterns (PAMPs), which are PRRs. The stimulation of PAMPs such as TLR-2 is responsible for hippocampal neurogenesis, while TLR-4 exhibits the opposite mechanisms (<xref ref-type="bibr" rid="B22">22</xref>). TLR-4 is involved in the development of learning and memory (<xref ref-type="bibr" rid="B23">23</xref>), and inhibits retinal neurogenesis and differentiation through pathways mediated by myeloid differentiation primary response protein (MYD)-88 and nuclear factor-κB (NF-κB) (<xref ref-type="bibr" rid="B24">24</xref>). The loss of MYD-88 in epithelial cells yields increased bacterial translocation and altered bacterial microbiota (<xref ref-type="bibr" rid="B25">25</xref>). TLR-5 controls intestinal microbial ecology, preventing dysbiosis (<xref ref-type="bibr" rid="B26">26</xref>). Nucleotide-binding oligomerization domain-containing protein (NOD)-like receptors (NLRs) are also determinants of microbial dysbiosis. Among NOD receptor subtypes, NOD1 is implicated in binding peptidoglycan from Gram-negative bacteria (<xref ref-type="bibr" rid="B27">27</xref>). NOD2 is involved in increased burden of commensals and mucosa-associated bacteria (<xref ref-type="bibr" rid="B28">28</xref>), its absence predisposing to dysbiosis. In contrast, NOD6 is involved in the maintenance of a stable intestinal microbial community (<xref ref-type="bibr" rid="B29">29</xref>). NOD2, which is responsible for intestinal homeostasis, activates kinase receptor-interacting protein (RIPK)-2 and NF-kB, which are involved in the control of the production of antimicrobial peptides (AMPs) and mucin. AMP expression is also influenced by flagellin and lipoproteins, which interact with TLR-5 on dendritic and epithelial cells (<xref ref-type="bibr" rid="B29">29</xref>). Additionally, some NLR proteins create a multiprotein complex known as the inflammasome. The inflammasome activates caspase-1, which processes interleukin (IL)-1β and IL-18 precursors. Overall, inflammasome activation results in IL-1β and IL-18 secretion and changes in several immune cell populations (<xref ref-type="bibr" rid="B30">30</xref>). Regarding the adaptive immune response, compelling evidence suggests that B cells play an important role in microbiota homeostasis through the secretion of immunoglobulin (Ig)A (<xref ref-type="bibr" rid="B31">31</xref>). IgA selection is promoted by T helper follicular cells. This mechanism of IgA secretion is regulated by death protein-1, which manages the microbiome at the intestinal level (<xref ref-type="bibr" rid="B32">32</xref>). Invariant natural killer T-cells are also involved in microbiota regulation (<xref ref-type="bibr" rid="B33">33</xref>). Specifically, a symbiotic relationship between the immune system in the intestine and the microbiota exists. In fact, the intestinal immune system protects the organism against pathogens germs, while the microbiota maintains the intestinal immune system, inducing secretion of IgG from plasma cells, IL-17- and IL-22-from helper T cells (Th-17 cells), which are situated in the mucosal lamina propria, and represent the mediators of microbiota-immune system crosstalk. IgA directly promotes colonization by mutualistic microbes, competing with invasive pathogens. IL-17 and IL-22 maintain the mucosal barrier system homeostasis, which protects the organism stimulating the expression anti-microbial molecules in intestinal epithelial cells. Moreover, T regulator (Treg) cells contribute to immune homeostasis in non-lymphoid tissues including the gastrointestinal tract, recruited by T-cell antigen receptor (TCR) and cytokine signals expression, differentiating into suppressive effector Treg cells with IL-10 production. IL-10 holds anti-inflammatory effect, contributing to preserve gut homeostasis. Dysbiosis is correlated to an increased susceptibility to intestinal inflammation, because of reduced IgA, IL-22, and IL-10 production, and IL-17R impairment (<xref ref-type="bibr" rid="B34">34</xref>). The activation of innate and adaptive immune responses at mucosal surfaces during inflammation, autoimmunity, and infection explains why microbiota composition could play an essential role in modulating immune response in other organs, such as the brain (<xref ref-type="bibr" rid="B35">35</xref>). Evidence from germ-free mice suggests correlations among an immature microglial phenotype, altered immune response, and brain pathology. This can be modulated by short-chain fatty acids and microbiota-derived bacterial fermentation products (<xref ref-type="bibr" rid="B36">36</xref>). Microglia are essential for the maintenance of tissue homeostasis, synaptic remodeling, and scavenging of pathogens, molecules and death cells, and have been associated with neuropsychiatric and neurological disease in humans (<xref ref-type="bibr" rid="B36">36</xref>). Under germ-free conditions, microglial polarization (especially M1&gt;M2) is reduced, suggesting that reduced complexity of microbiota impairs microglial function (<xref ref-type="bibr" rid="B36">36</xref>). Several neurological diseases correlate with blood–brain barrier impairment, in which microbiota dysregulation may play a role. These include Parkinson's disease, Alzheimer's disease, several mental disorders, and autism spectrum disorders (<xref ref-type="bibr" rid="B24">24</xref>). Experimental research has hypothesized that increased blood–brain barrier permeability might be induced by the loss of normal microbiota diversity (<xref ref-type="bibr" rid="B37">37</xref>). Besides, microbiota diversity is not only associated with blood–brain barrier permeability, but also plays a crucial role in hippocampal and microglial brain morphology (<xref ref-type="bibr" rid="B24">24</xref>). Additionally, several neurological disorders are associated with an enhanced local inflammatory response, which can contribute to systemic cytokine release and increased tissue permeability, thus altering microbiota homeostasis (<xref ref-type="bibr" rid="B24">24</xref>). In fact, dysbiosis of the intestinal microbiota in neurocritically ill patients has been correlated to mortality at 180 days (<xref ref-type="bibr" rid="B38">38</xref>).</p>
</sec>
<sec>
<title>The Brain–Gut–Microbiota Axis in AIS</title>
<p>Local and systemic inflammatory responses are enhanced after AIS (<xref ref-type="bibr" rid="B4">4</xref>). Monocytes (innate response) enter the brain within 24 h, reaching maximum numbers around 3–5 days after AIS (<xref ref-type="bibr" rid="B39">39</xref>). They differentiate into macrophages with a distinct molecular signature compared to microglia (<xref ref-type="bibr" rid="B40">40</xref>). Inflammatory monocytes have been shown to exert protective effects following AIS in mice (<xref ref-type="bibr" rid="B41">41</xref>), whereas the role of patrolling monocytes is less clear (<xref ref-type="bibr" rid="B42">42</xref>). Neutrophils play a controversial role in AIS. Although several mechanisms (<xref ref-type="bibr" rid="B43">43</xref>) (such as the production of reactive oxygen species and the release of metalloproteinases) have been attributed to neutrophils, the existence of neuroprotective N2 neutrophils has also been reported (<xref ref-type="bibr" rid="B44">44</xref>). A recent study in mice identified the triggering receptor expressed on myeloid cells (TREM)-1 as an interesting target for pharmacotherapies aimed at reducing the pro-inflammatory response of peripheral and intestinal myeloid cells after AIS (<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>TREM1 is a potent enhancer of innate immune responses, it acts by synergizing with classical PRRs, thus inducing the production of proinflammatory cytokines and chemokines, including IL-8, monocyte chemoattractant protein-1 (MCP-1), MCP-3 and macrophage inflammatory (MIP-1α), and inhibition of IL-10 (<xref ref-type="bibr" rid="B45">45</xref>). Furthermore, neurotoxic mechanisms activate the release of pro-inflammatory cytokines such as interleukin-21 from cluster of differentiation (CD)-4<sup>+</sup> T cells within 24 h after AIS (<xref ref-type="bibr" rid="B46">46</xref>) and IL-17 from γδT-cells (<xref ref-type="bibr" rid="B47">47</xref>). IL-17 acts by recalling neutrophils through chemokine release, whereas IL-21 and perforin exert direct neurotoxic effects in the brain (<xref ref-type="bibr" rid="B48">48</xref>). Clinical trials have failed to provide evidence of beneficial effects of neutrophil blockade in AIS patients (<xref ref-type="bibr" rid="B49">49</xref>). γδT-cells express the chemokine receptor (CCR)-6, which is essential for their infiltration into the AIS lesion (<xref ref-type="bibr" rid="B47">47</xref>). In the first 2-3 days after AIS, lymphocytes arrive at the ischemic lesion (adaptive response) (<xref ref-type="bibr" rid="B4">4</xref>). In particular, T helper-1 and-17 subpopulations activate neuroinflammation, whereas regulatory T-cells have a neuroprotective action due to their anti-inflammatory properties (<xref ref-type="bibr" rid="B50">50</xref>). The consequences of this remain unclear, as detrimental effects to regulatory T cells after AIS have been reported (<xref ref-type="bibr" rid="B51">51</xref>). Release into the systemic circulation of cytokines and chemokines produced in the brain after AIS may exert a potential influence on microbiota composition and dysbiosis (<xref ref-type="bibr" rid="B52">52</xref>). T lymphocytes, especially regulatory and γδT-cells, play a pivotal role in how the microbiota can modify infarct size and neurological function after AIS (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B53">53</xref>). T lymphocytes have been shown to migrate from the Peyer patches of the small intestine or from the intestinal lamina propria to the brain and/or the leptomeninges following AIS (<xref ref-type="bibr" rid="B7">7</xref>). Increased gut permeability after AIS can result in bacterial translocation and lung infection in mice (<xref ref-type="bibr" rid="B17">17</xref>). Local inflammatory responses at the intestinal level in AIS are depicted in <xref ref-type="fig" rid="F2">Figure 2</xref>. Despite some degree of controversy arising from study heterogeneity, pneumonia—presumably secondary to immune dysregulation and bacterial translocation—is the most common acute complication after AIS (<xref ref-type="bibr" rid="B54">54</xref>). Immunogenic endotoxins from the microbiota, such as lipopolysaccharide (LPS), can promote neuroinflammation by a direct mechanism and/or by inducing migration of peripheral immune cells to the brain (<xref ref-type="bibr" rid="B55">55</xref>). An interesting experimental study showed that AIS in cynomolgus monkeys induced a long-term, persistent increase in levels of LPS and pro-inflammatory cytokines in plasma, which correlated with the relative abundance of the phylum Bacteroidetes in the gut microbiota. Additionally, intestinal dysbiosis and mucosal damage persisted for up to 12 months after AIS (<xref ref-type="bibr" rid="B52">52</xref>). Clinical evidences (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>) concluded that after AIS the commensal flora changes in favor of opportunistic pathogens, such as <italic>Enterobacter, Megasphaera, Oscillibacter, Desulfovibrio, Odoribacter</italic>, and <italic>Akkermansia</italic> (<xref ref-type="bibr" rid="B58">58</xref>), instead of commensals such as <italic>Bacteroides, Prevotella</italic>, and <italic>Faecalibacterium</italic>. Although several mechanisms involved in the microbiota-regulated immune response after AIS have been identified, our understanding about microbiota modulation following AIS is incompletely understood.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Local intestinal inflammatory response in stroke. As the first intestinal response to AIS, the enteric barrier is disrupted, thus compromising the ability of the microbiota to defend against intestinal pathogens. The microbiota stimulates release of metabolites, neurotransmitters, indoles, short-chain fatty acids, and bile acids that can reach the brain, thus modulating neurons, microglia, astrocytes, and neurovascular unit function. Vagal afference activate neuroendocrine system to release peptides [peptide YY (PYY), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK)], as well as inflammatory response to enhance pro-inflammatory cytokines release (e.g., interleukin (IL)-21) from cluster of differentiation (CD)-4<sup>+</sup> T-cells and IL-17 from γδT-cells. IL-17 acts to recall neutrophils by releasing chemokines. Moreover, T lymphocytes can migrate from the Peyer patches of the small intestine or from the intestinal lamina propria to the brain and/or the leptomeninges. As depicted in the inset, the loss of myeloid differentiation primary response protein (MYD)-88 in epithelial cells results in increased bacterial translocation and altered bacterial microbiota. Moreover, nucleotide-binding oligomerization domain-containing protein (NOD)-like receptors-6 (NLRP6) are involved in the maintenance of a stable intestinal microbial community. Usually, NLR proteins create a multiprotein complex named the inflammasome, activating IL-1β and IL-18 secretion and changes in several immune cell populations. B-cells also play an important role in microbiotic homeostasis through secretion of immunoglobulin A, promoted by TCD4+ on plasma cells. Additionally, dendritic cells are stimulated by T regulatory cells to increase the secretion of IL-10. [PYY, peptide YY; GLP-1, glucagon-like peptide-1; CCK, cholecystokinin; IL, interleukin; CD, cluster of differentiation; MYD, myeloid differentiation primary response protein; NOD, nucleotide binding oligomerization domain-containing protein; NLRP, nucleotide-binding oligomerization domain-containing protein receptor; CRH, corticotropin releasing hormone; ACTH, adrenocorticotropic hormone].</p>
</caption>
<graphic xlink:href="fneur-11-00598-g0002"></graphic>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Clinical Implications</title>
<p>Alterations in the gut microbiota composition have been identified in various neurological diseases, including cognitive dysfunction, autism, neurodegenerative disorders, and cerebrovascular diseases (<xref ref-type="bibr" rid="B24">24</xref>). The gut microbiome is pivotal for brain function and behavior, as demonstrated by the fact that gut dysbiosis is associated with impairment of the blood–brain barrier, behavioral deficits, and alterations of synaptic plasticity (<xref ref-type="bibr" rid="B59">59</xref>). We will discuss how alterations in the gut microbiota during AIS affect neurologic outcomes, risk factors, and occurrence of AIS-associated pneumonia, as well as cardiovascular, gastrointestinal, hepatic, renal complications and development of the multiple organ dysfunction syndrome, thus potentially affecting clinical outcomes and functional recovery (<xref ref-type="fig" rid="F3">Figure 3</xref>) (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Clinical implications of intestinal dysbiosis after ischemic stroke. Changes caused by stroke on the gut microbiota can induce neurological complications, stroke-associated pneumonia, cardiac dysfunction, gastrointestinal complications, and renal dysfunction, with possible development of the systemic inflammatory response and multiple organ dysfunction syndromes. [MODS, multiple organ dysfunction syndrome].</p>
</caption>
<graphic xlink:href="fneur-11-00598-g0003"></graphic>
</fig>
<sec>
<title>Influence of Gut Dysbiosis on AIS Outcomes</title>
<p>Gut dysbiosis in AIS patients is associated with host metabolism and inflammation (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). Increased levels of opportunistic pathogens in the gut have been associated with higher risk of developing AIS (<xref ref-type="bibr" rid="B62">62</xref>). A clinical study that compared asymptomatic controls to patients with AIS reported significant changes in the gut microbiota composition in terms of increased opportunistic pathogens, with this finding persisting for at least 3 weeks after AIS (<xref ref-type="bibr" rid="B57">57</xref>). Gut dysbiosis was measured in AIS patients by developing a score called the “stroke dysbiosis index (SDI),” which has shown good correlation in predicting severe stroke and unfavorable outcome (<xref ref-type="bibr" rid="B56">56</xref>).</p>
</sec>
<sec>
<title>AIS Risk Factors and Gut Dysbiosis</title>
<p>AIS patients often show significant changes in microbial flora that may be independent of relevant comorbidities (hypertension, age, and type 2 diabetes) (<xref ref-type="bibr" rid="B56">56</xref>). However, alterations in the gut microbiota are known to elicit hypertension in rats, raising doubts as to the preceding evidence (<xref ref-type="bibr" rid="B63">63</xref>). Like hypertension, obesity and body composition in both sexes are associated with metabolic syndrome and higher cardiovascular and cerebrovascular risk, which are influenced by inflammation and gut permeability, thereby suggesting a role of gut microbiota in the prevention of these diseases (<xref ref-type="bibr" rid="B64">64</xref>).</p>
<sec>
<title>Hypertension</title>
<p>Diabetes and hypertension have been identified as systemic activators of immune response and are two of the most important risk factors for AIS (<xref ref-type="bibr" rid="B65">65</xref>). Intensive management of hypertension in AIS patients is recommended to reduce the risk of chronic myocardial dysfunction and cardiac remodeling (<xref ref-type="bibr" rid="B66">66</xref>–<xref ref-type="bibr" rid="B68">68</xref>). Hypertensive and pre-hypertensive patients have a different gut microbiota composition as compared to non-hypertensive patients. The finding of altered microbiota composition in pre-hypertensive patients suggests that dysbiosis most commonly appears before clinical hypertension, rather than hypertension being the causative factor of dysbiosis (<xref ref-type="bibr" rid="B63">63</xref>).</p>
</sec>
<sec>
<title>Obesity and Diabetes Mellitus</title>
<p>These metabolic disorders are known to increase the risk of cerebrovascular diseases, such as AIS (<xref ref-type="bibr" rid="B6">6</xref>). The gut microbiota plays paramount roles in the regulation of satiety, thermogenesis, and energy balance, due to its ability to manage host immune cell activation and maturation and neuro-endocrine and hormonal functions. Furthermore, dysbiosis activates pro-inflammatory mechanisms that are implicated in diabetes and cardiovascular disease. In particular, trimethylamine N-oxide (TMAO) may be implicated in the pathogenesis of cardiovascular, metabolic and cerebrovascular diseases (<xref ref-type="bibr" rid="B69">69</xref>). In fact, in patients with type I diabetes, higher concentrations of plasma TMAO were associated with mortality, cardiovascular events, and micro and macrovascular complications (<xref ref-type="bibr" rid="B70">70</xref>). Elevated TMAO levels within the first hours after AIS are associated with poor stroke outcomes (<xref ref-type="bibr" rid="B71">71</xref>).</p>
</sec>
<sec>
<title>Vascular Dysfunction</title>
<p>Vascular dysfunction can influence mortality and outcome following AIS. Bacterial metabolites such as short-chain fatty acids, nitrites, flavanol, TMAO, indoles, and sulfidic acid have been identified as causative factors of vascular dysfunction. Short chain fatty acids and sulfidic acid are particularly capable of inducing vasodilatation, whereas indole and trimethylamine N-oxide increase the production of reactive oxygen species, thus reducing cerebral vasodilatation (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B72">72</xref>).</p>
</sec>
<sec>
<title>Aging</title>
<p>According to recent investigations, the gut microbiota undergoes several modifications during the life course. Specifically, immune function, microbiota variability, and anti-inflammatory properties are reduced in older adults.</p>
</sec>
</sec>
<sec>
<title>AIS-Associated Pneumonia</title>
<p>The mechanism underlying immune dysregulation and reduced antimicrobial defense after AIS is still unclear. Infection rates range between 5 and 65%; this variability is attributed to the heterogeneity of the current definition (<xref ref-type="bibr" rid="B73">73</xref>). Stanley et al. suggested a role for bacterial translocation in the pathogenesis of AIS-associated pneumonia (<xref ref-type="bibr" rid="B17">17</xref>). Pneumonia is a typical example of dysbiosis-related infection. Pneumonia correlates with an increased mortality rate (<xref ref-type="bibr" rid="B73">73</xref>). A recent meta-analysis including 137,817 AIS patients from 87 studies confirmed an overall infection incidence of 30%, with pneumonia accounting for up to 10% (<xref ref-type="bibr" rid="B74">74</xref>). Dysphagia occurs in 50–55% of AIS patients (<xref ref-type="bibr" rid="B75">75</xref>), and the incidence of AIS-associated aspiration pneumonia ranges from 4 to 57% (<xref ref-type="bibr" rid="B76">76</xref>). <italic>Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli</italic>, and <italic>Enterobacter</italic> species are commonly identified, especially in the intensive care unit (<xref ref-type="bibr" rid="B77">77</xref>). Another important factor leading to pneumonia after AIS is immunosuppression (<xref ref-type="bibr" rid="B4">4</xref>). In post-AIS mice, aspiration of only 200 colony-forming units of <italic>Streptococcus pneumoniae</italic> was enough to trigger pneumonia and bacteremia compared to sham-operated mice, in which up to 20,0000 colony forming units were required to induce pneumonia (<xref ref-type="bibr" rid="B78">78</xref>).</p>
</sec>
<sec>
<title>Cardiovascular Complications</title>
<p>The incidence of cardiovascular events is increased after AIS (<xref ref-type="bibr" rid="B79">79</xref>), accounting for up to 39% of complications in AIS patients without previous cardiac events (<xref ref-type="bibr" rid="B80">80</xref>). The most common disturbances include cardiac arrhythmias, stress-induced cardiomyopathy (Takotsubo syndrome), autonomic dysfunction, myocardial infarction, and arterial hypertension (<xref ref-type="bibr" rid="B81">81</xref>). According to recent evidence, the occurrence of cardiovascular and cerebrovascular diseases correlates with dysbiosis (<xref ref-type="bibr" rid="B82">82</xref>). TMAO, a byproduct of the intestinal microbiota, is a potential novel biomarker of cardiovascular events, including AIS (<xref ref-type="bibr" rid="B83">83</xref>), and also associated with poor outcomes (<xref ref-type="bibr" rid="B84">84</xref>).</p>
</sec>
<sec>
<title>Gastrointestinal Complications</title>
<p>Water and nutrients are absorbed by the gut–blood barrier, which also prevents the passage of toxins and pathogens into the blood (<xref ref-type="bibr" rid="B85">85</xref>). Intestinal permeability is modified by AIS-induced inflammation, thus enhancing microbiota dysregulation (<xref ref-type="bibr" rid="B85">85</xref>). Moreover, increased intestinal permeability has been associated with greater AIS severity (<xref ref-type="bibr" rid="B85">85</xref>), as well as imbalance of the intestinal flora in favor of pathogens, thereby influencing outcome and post-AIS mortality (<xref ref-type="bibr" rid="B86">86</xref>). After AIS, up to 50% of patients develop gastrointestinal complications such as hemorrhage, intestinal paralysis, bowel incontinence, and dysphagia, which are considered partially responsible for poor neurological outcomes and increased mortality (<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B87">87</xref>). This deterioration of outcomes is mainly attributed to increased immune activation in the gut, with systemic migration of lymphocytes to the brain (<xref ref-type="bibr" rid="B53">53</xref>). It is interesting to note that patients with Crohn's disease have an increased susceptibility to AIS, further implying a bidirectional association between gut dysbiosis and AIS (<xref ref-type="bibr" rid="B88">88</xref>).</p>
</sec>
<sec>
<title>Hepatic Complications</title>
<p>The potential association between liver disease, AIS, and gut microbiota dysregulation is poorly understood (<xref ref-type="bibr" rid="B89">89</xref>). Since the systemic coagulation cascade is managed mostly by pro- and anticoagulant factors produced by the liver, hepatic dysfunction can cause coagulopathies with bleeding or thrombotic complications, and has consequently been identified as an important risk factor for AIS (<xref ref-type="bibr" rid="B90">90</xref>). Among hepatic disorders, non-alcoholic fatty acid disease (NAFLD), cirrhosis, and liver fibrosis are the most common factors associated with AIS (<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B91">91</xref>). The liver plays a major role in the biotransformation of drugs and toxins. Trimethylamine is converted by hepatic enzymes into TMAO, which is also implicated in platelet hyperreactivity, atherosclerosis (<xref ref-type="bibr" rid="B92">92</xref>), inflammation, and cholesterol metabolism (<xref ref-type="bibr" rid="B93">93</xref>). The gut microbiota is able to modulate cholesterol transport by activating of specific enzymes that suggests a role in modulation of risk factors involved in the development of AIS (<xref ref-type="bibr" rid="B94">94</xref>).</p>
</sec>
<sec>
<title>Renal Complications</title>
<p>Risk factors for kidney injury and AIS are very similar, and atherosclerosis plays a crucial role in both contexts (<xref ref-type="bibr" rid="B95">95</xref>). In a recent meta-analysis, the incidence of acute kidney injury in AIS patients reached up to 9.6%, and was associated with increased overall mortality rate (<xref ref-type="bibr" rid="B96">96</xref>), in-hospital mortality, and neurological deterioration (<xref ref-type="bibr" rid="B97">97</xref>). Uremic toxins are waste products of microbiota that can cross the intestinal blood–barrier because of increased gut permeability after AIS, and thus reach the systemic circulation (<xref ref-type="bibr" rid="B98">98</xref>). In support of a purported gut–brain–kidney axis, an experimental study demonstrated that rats affected by both acute kidney injury and AIS displayed neuronal loss; glial, macrophage, and microglial upsurge; and increased circulating IL-6 and IL-1β levels (<xref ref-type="bibr" rid="B99">99</xref>). Following a systemic inflammatory process, high level of microbiota waste products such as TMAO are found in patients with chronic kidney disease, suggesting that TMAO is inversely associated with glomerular filtration rate and should be considered as a new clinical marker of renal medullary damage, hypertension, and heart disease (<xref ref-type="bibr" rid="B100">100</xref>). TMAO plasma concentrations are elevated in patients with chronic kidney disease, and predict poor long-term survival; in animal models, TMAO is associated with tubulointerstitial fibrosis and renal dysfunction (<xref ref-type="bibr" rid="B101">101</xref>).</p>
</sec>
<sec>
<title>Multiple Organ Dysfunction Syndrome</title>
<p>The gut is the most colonized system of the body. It is home to a broad range of commensal and pathogenic microorganisms—up to trillions of different types of bacteria. The intestinal mucosal barrier activates a specialized local immune response due to the existence of organized gut-associated lymphoid tissue (GALT) (<xref ref-type="bibr" rid="B102">102</xref>). Leaky gut (i.e., increased intestinal permeability) can determine the release of intestinal lumen bacteria and toxins into the circulation, thus enhancing systemic inflammation and causing sepsis or a systemic inflammatory response (<xref ref-type="bibr" rid="B9">9</xref>). Indeed, the systemic inflammatory response syndrome has been detected as a complication of systemic inflammation after AIS (<xref ref-type="bibr" rid="B9">9</xref>). A study conducted on 1,500 AIS patients revealed that systemic inflammation at admission was associated with infarct volume, functional outcome, and clinical severity (<xref ref-type="bibr" rid="B103">103</xref>). Moreover, within the first days after AIS, white blood cell counts, body temperature, and C-reactive protein levels were higher; therapeutic thrombolysis attenuated this inflammatory response (<xref ref-type="bibr" rid="B103">103</xref>). Systemic inflammatory response can result in MODS in up to 12% of AIS patients, increasing the mortality rate up to 80%. (104) Among risk factors for MODS after AIS, a low Glasgow Coma Score, advanced age, hypoglycemia, hyperglycemia, leukocytosis, and history of chronic organ dysfunction have been identified (<xref ref-type="bibr" rid="B104">104</xref>). Unfortunately, clinical data on multiorgan failure and systemic inflammatory response in AIS patients is scant, and their correlation with microbiota manipulation poor.</p>
</sec>
</sec>
<sec id="s4">
<title>Therapeutic Strategies</title>
<sec>
<title>Diet</title>
<p>Diet is a major determinant of gut microbiota composition. Indeed, dietary diversity has been associated with regulation of insulin resistance, susceptibility to infections, and TMAO concentration, among other changes (<xref ref-type="bibr" rid="B105">105</xref>). The production of TMAO by gut microbiota can be increased by high intake of L-carnitine and phosphatidylcholine, which is an excellent dietary source of choline commonly found in red meat and eggs (<xref ref-type="bibr" rid="B106">106</xref>). Moreover, antibiotic treatment has been found to reduce TMAO generation, whereas, discontinuation of antibiotics caused an increase in TMAO levels (<xref ref-type="bibr" rid="B84">84</xref>). High-fat diets such as the ketogenic diet [commonly used for its antiseizure properties by increasing serum ketones and reducing neuronal apoptosis (<xref ref-type="bibr" rid="B107">107</xref>)] have also been found to increase TMAO concentration in humans (<xref ref-type="bibr" rid="B108">108</xref>), whereas the Mediterranean diet and vegetarian diets reduced TMAO production (<xref ref-type="bibr" rid="B94">94</xref>). The Mediterranean diet has been widely investigated in recent decades for its potential health benefits. Indeed, the consumption of cereals, nuts, vegetables, legumes, fruit, and fish can mitigate the incidence of neurodegenerative disorders, psychiatric diseases (<xref ref-type="bibr" rid="B109">109</xref>), and cardiovascular dysfunction (<xref ref-type="bibr" rid="B110">110</xref>). A study reported that patients with higher Mediterranean Diet Score Stratification had a lower <italic>Firmicutes/Bacteroidetes</italic> ratio, thus suggesting anti-inflammatory effects of the Mediterranean diet and its modulation of gut microbiota (<xref ref-type="bibr" rid="B111">111</xref>). Protein-rich diets have been associated with conflicting results. Although amino acids are considered essential for synthesis of neurotransmitters (<xref ref-type="bibr" rid="B112">112</xref>), long-term adherence to a high-protein diet is associated with harmful effects on gut microbiota composition (<xref ref-type="bibr" rid="B113">113</xref>). There has been growing interest in the role of dietary fiber in gut microbiota composition. Fiber is mainly fermented by <italic>Firmicutes</italic> and other bacterial species, thus increasing the production of short chain fatty acids (SCFAs) such as acetate, propionate, and butyrate (<xref ref-type="bibr" rid="B114">114</xref>). SCFAs have also been suggested to improve post-stroke recovery via immune mechanisms (<xref ref-type="bibr" rid="B115">115</xref>). There is little evidence on the impact of fiber-rich diets on AIS outcome, but, as demonstrated in experimental settings, the immunomodulatory effect of fibers seems to be anti-inflammatory.</p>
</sec>
<sec>
<title>Probiotics and Prebiotics</title>
<p>Probiotics are defined as “live micro-organisms which induce benefits in the host,” and although they are largely assumed to be safe and useful, four broad categories of adverse effects have been identified: (1) systemic infections, (2) deleterious metabolic activities, (3) excessive immune stimulation, and (4) undesired gene transfer (<xref ref-type="bibr" rid="B116">116</xref>). Importantly, in immunocompromised patients, probiotic administration has been associated with the development of sepsis (<xref ref-type="bibr" rid="B116">116</xref>). On the other hand, probiotics act through acid lactic fermentation in the gut, thus improving the balance between pathogens and commensals, enhancing immune regulation of the intestinal system, and inhibiting bacterial toxin production (<xref ref-type="bibr" rid="B117">117</xref>). Prebiotics are not digested in the small bowel, but are active in the colon, where they are fermented by bacteria. Carbohydrates are an example of prebiotics (<xref ref-type="bibr" rid="B117">117</xref>). Prebiotics are capable of influencing the production of SCFAs and regulating mucin production and local inflammatory response into the GALT, thus stimulating phagocytosis by macrophages (<xref ref-type="bibr" rid="B117">117</xref>). In a meta-analysis of thirteen clinical trials, treatment with prebiotics reduced neither intensive care unit mortality nor in-hospital mortality. However, administration of prebiotics resulted in declines in both incidence of pneumonia associated with intensive care unit stay and in-hospital length-of-stay (<xref ref-type="bibr" rid="B118">118</xref>). Therefore, based on this limited clinical evidence, prebiotics might be hypothesized to reduce the risk of pneumonia, which is particularly high in AIS patients (<xref ref-type="bibr" rid="B73">73</xref>).</p>
</sec>
<sec>
<title>Antibiotics</title>
<p>To date, no clear evidence is available in support of prophylactic antibiotic treatment within the first hours after AIS to control dysbiosis (<xref ref-type="bibr" rid="B77">77</xref>). A recent 1,224-patient study demonstrated that prophylactic antibiotics administered immediately following AIS, and primarily in those patients affected by post-AIS dysphagia, did not reduce the incidence of pneumonia (<xref ref-type="bibr" rid="B119">119</xref>). A second prospective randomized study confirmed a reduction in overall infections after prophylactic antibiotic therapy with 2 g of intravenous ceftriaxone every 24 h for 4 days relative to standard care, but this did not affect the incidence of post-AIS pneumonia or functional outcome scores at 2 months (<xref ref-type="bibr" rid="B120">120</xref>). In 2017, a randomized controlled trial of 227 patients compared standard care plus ultrasensitive procalcitonin-guided antibiotic treatment to standard care alone. When procalcitonin reached a value greater than 0.05 ng/ml, prophylactic antibiotics were administered following local guidelines. There were no beneficial effects on functional outcome at 90 days, nor on mortality rate (<xref ref-type="bibr" rid="B77">77</xref>).</p>
</sec>
<sec>
<title>Fecal Transplantation, Intra-Gastric Treatments, and Microbial Metabolites</title>
<sec>
<title>Fecal Transplantation</title>
<p>Gut microbiota dysbiosis can influence the severity of brain injury (<xref ref-type="bibr" rid="B7">7</xref>). The effect of intestinal bacteria on neuronal function is defined as <italic>psychobiotics</italic>. Fecal microbiota transplantation is the transfer of donor fecal microbiota from healthy people to sick patients (<xref ref-type="bibr" rid="B121">121</xref>), and it has recently been identified as a possible strategy to correct dysbiosis in patients with neuropsychiatric disorders and those affected by AIS (<xref ref-type="bibr" rid="B122">122</xref>). Antibiotic administration reduced neurological impairment, blood lipid levels, and infarct volume, while transplanting stool rich in SCFAs (especially butyric acid) led to microbiota remodeling, increasing <italic>Lactobacillus</italic> species and improving intestinal microbiota, thus positively modulating the brain ischemic response (<xref ref-type="bibr" rid="B123">123</xref>). Fecal microbiota transplantation has proven effective for intestinal dysbiosis in clinical settings, although its use was associated with secondary bacteremia from <italic>E. coli</italic> infection in two patients with recurrent <italic>Clostridioides difficile</italic> infection, transmitted by the donor fecal microbiota (<xref ref-type="bibr" rid="B124">124</xref>). Nevertheless, this treatment is recognized as a novel alternative to antibiotic therapies against primary <italic>C. difficile</italic> infection in small cohorts of patients (<xref ref-type="bibr" rid="B124">124</xref>). Taken together, these studies suggest that fecal transplantation can broadly affect intestinal microbiota in recipients.</p>
</sec>
<sec>
<title>Intragastric Treatments and Microbial Metabolites</title>
<p>Intragastric treatment with <italic>Clostridium butyricum</italic> after bilateral common carotid artery occlusion resulted in reduced neuronal damage and cognitive impairment in rodents (<xref ref-type="bibr" rid="B125">125</xref>). These beneficial effects might be at least partially related to production of the microbial metabolite butyrate, which has been shown to be neuroprotective in models of AIS (<xref ref-type="bibr" rid="B126">126</xref>). In another study in rats, sodium butyrate mitigated blood–brain barrier permeability following AIS by reducing the activity of matrix metalloproteinase-9 (<xref ref-type="bibr" rid="B127">127</xref>). Among metabolites, GABA plays an important role in tryptophan–tryptamine–serotonin metabolism. Tryptophan is a precursor of both host and microbial metabolites (such as kynurenic acid (<xref ref-type="bibr" rid="B128">128</xref>) and quinolinic acid, which is associated with neurodegenerative diseases by neurotoxic modulation) with anti-inflammatory and neuroprotective properties (<xref ref-type="bibr" rid="B129">129</xref>). Further studies are underway and future research will be needed to reveal the impact of fecal microbiota manipulation and metabolite activity on neuronal function.</p>
</sec>
</sec>
<sec>
<title>Environment</title>
<p>The environment has a great impact on daily life and health. The “halogenome theory of evolution” suggests that both the host species and the symbiotic microbiota, which together form a unit known as the <italic>halobiont</italic>, exert genetic selection in response to environmental demand (e.g., stress, temperature, diet, industry, etc.) (<xref ref-type="bibr" rid="B6">6</xref>). An example of harmful environment is contact with heavy metals like cadmium, mercury, and arsenic, which can modify the immune system towards nuclear changes and disturb gut microbiota composition (<xref ref-type="bibr" rid="B6">6</xref>). Likewise, bisphenol A, a compound widely used by the plastic industry, can disrupt intestinal microbiota with adverse effects (<xref ref-type="bibr" rid="B6">6</xref>). Antibiotic abuse can increase their levels in the environment, contaminating the soil, bodies of water, and waste, thus causing huge consequences at the global level (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>In summary, various factors such as diet, probiotics, prebiotics, antibiotics, and the environment seem to be associated with meaningful changes in the gut microbiota. Alterations in both function and composition of this microbiota seems to profoundly affect risks and outcomes in AIS patients. As we move forward, the challenge will be to determine causal relationships and develop strategies to optimize microbiota composition in order to reduce risk and modulate outcomes and recovery (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Therapeutic strategies. Pros and cons of the therapeutic strategies described in the literature to date for microbiota manipulation in stroke patients.</p>
</caption>
<graphic xlink:href="fneur-11-00598-g0004"></graphic>
</fig>
</sec>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusions</title>
<p>Translational microbiome research against the enhanced systemic inflammatory immune and neuroendocrine responses and on the impact of modulation of the environment, diet, and drugs on the so-called halobiont in AIS patients are limited. Since only few of these studies have demonstrated that antibiotic treatment, probiotics, exercise, or environmental changes could be essential for microbiota and outcome modulation, microbiota dysregulation after AIS remains a challenging target for new therapies.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>DB wrote the manuscript. DB, PR, PP-C, and FC designed the review. PP-C, FC, CS, PP, and PR revised the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank Mr. Filippe Vasconcellos (São Paulo, Brazil) for his assistance in editing the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> Brazilian Council for Scientific and Technological Development (CNPq) and Rio de Janeiro State Research Foundation (FAPERJ).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Feigin</surname><given-names>VL</given-names></name><name><surname>Nguyen</surname><given-names>G</given-names></name><name><surname>Cercy</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>CO</given-names></name><name><surname>Alam</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016</article-title>. <source/>N Engl J Med. (<year>2018</year>) <volume>379</volume>:<fpage>2429</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1804492</pub-id><pub-id pub-id-type="pmid">30575491</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poorthuis</surname><given-names>MHF</given-names></name><name><surname>Algra</surname><given-names>AM</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><name><surname>Kappelle</surname><given-names>LJ</given-names></name><name><surname>Klijn</surname><given-names>CJM</given-names></name></person-group>. <article-title>Female-and male-specific risk factors for stroke a systematic review and meta-analysis</article-title>. <source/>JAMA Neurol. (<year>2017</year>) <volume>74</volume>:<fpage>75</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2016.3482</pub-id><pub-id pub-id-type="pmid">27842176</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Learoyd</surname><given-names>AE</given-names></name><name><surname>Woodhouse</surname><given-names>L</given-names></name><name><surname>Shaw</surname><given-names>L</given-names></name><name><surname>Sprigg</surname><given-names>N</given-names></name><name><surname>Bereczki</surname><given-names>D</given-names></name><name><surname>Berge</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Infections up to 76 days after stroke increase disability and death</article-title>. <source/>Transl Stroke Res. (<year>2017</year>) <volume>8</volume>:<fpage>541</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s12975-017-0553-3</pub-id><pub-id pub-id-type="pmid">28752410</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samary</surname><given-names>CS</given-names></name><name><surname>Pelosi</surname><given-names>P</given-names></name><name><surname>Leme Silva</surname><given-names>P</given-names></name><name><surname>Rocco</surname><given-names>PRM</given-names></name></person-group>
<article-title>Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy</article-title>. <source/>Crit Care. (<year>2016</year>) <volume>20</volume>:<fpage>391</fpage>
<pub-id pub-id-type="doi">10.1186/s13054-016-1573-1</pub-id><pub-id pub-id-type="pmid">27923376</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arpaia</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Dikiy</surname><given-names>S</given-names></name><name><surname>van der Veeken</surname><given-names>J</given-names></name><name><surname>DeRoos</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Metabolites produced by commensal bacteria promote peripheral regulatory t-cell generation</article-title>. <source/>Nature. (<year>2013</year>) <volume>504</volume>:<fpage>451</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/nature12726</pub-id><pub-id pub-id-type="pmid">24226773</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cryan</surname><given-names>JF</given-names></name><name><surname>O'Riordan</surname><given-names>KJ</given-names></name><name><surname>Cowan</surname><given-names>CSM</given-names></name><name><surname>Sandhu</surname><given-names>K V.</given-names></name><name><surname>Bastiaanssen</surname><given-names>TFS</given-names></name><name><surname>Boehme</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>The microbiota-Gut-Brain axis</article-title>. <source/>Physiol Rev. (<year>2019</year>) <volume>99</volume>:<fpage>1877</fpage>–<lpage>2013</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00018.2018</pub-id><pub-id pub-id-type="pmid">31460832</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benakis</surname><given-names>C</given-names></name><name><surname>Brea</surname><given-names>D</given-names></name><name><surname>Caballero</surname><given-names>S</given-names></name><name><surname>Faraco</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ t cells</article-title>. <source/>Nat Med. (<year>2016</year>) <volume>22</volume>:<fpage>516</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4068</pub-id><pub-id pub-id-type="pmid">27019327</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houlden</surname><given-names>A</given-names></name><name><surname>Goldrick</surname><given-names>M</given-names></name><name><surname>Brough</surname><given-names>D</given-names></name><name><surname>Vizi</surname><given-names>ES</given-names></name><name><surname>Lénárt</surname><given-names>N</given-names></name><name><surname>Martinecz</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Brain injury induces specific changes in the caecal microbiota of mice via altered autonomic activity and mucoprotein production</article-title>. <source/>Brain Behav Immun. (<year>2016</year>) <volume>57</volume>:<fpage>10</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.04.003</pub-id><pub-id pub-id-type="pmid">27060191</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>PR</given-names></name><name><surname>González-Navajas</surname><given-names>JM</given-names></name><name><surname>Jansen</surname><given-names>NJG</given-names></name></person-group>. <article-title>The digestive tract as the origin of systemic inflammation</article-title>. <source/>Crit Care. (<year>2016</year>) <volume>20</volume>:<fpage>279</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-016-1458-3</pub-id><pub-id pub-id-type="pmid">27751165</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barugh</surname><given-names>AJ</given-names></name><name><surname>Gray</surname><given-names>P</given-names></name><name><surname>Shenkin</surname><given-names>SD</given-names></name><name><surname>MacLullich</surname><given-names>AMJ</given-names></name><name><surname>Mead</surname><given-names>GE</given-names></name></person-group>. <article-title>Cortisol levels and the severity and outcomes of acute stroke: a systematic review</article-title>. <source/>J Neurol. (<year>2014</year>) <volume>261</volume>:<fpage>533</fpage>–<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-013-7231-5</pub-id><pub-id pub-id-type="pmid">24477489</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehrwein</surname><given-names>EA</given-names></name><name><surname>Orer</surname><given-names>HS</given-names></name><name><surname>Barman</surname><given-names>SM</given-names></name></person-group>. <article-title>Overview of the anatomy, physiology, and pharmacology of the autonomic nervous system</article-title>. <source/>Compr Physiol. (<year>2016</year>) <volume>6</volume>:<fpage>1239</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1002/cphy.c150037</pub-id><pub-id pub-id-type="pmid">27347892</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>SH</given-names></name><name><surname>Pothoulakis</surname><given-names>C</given-names></name><name><surname>Mayer</surname><given-names>EA</given-names></name></person-group>. <article-title>Principles and clinical implications of the brain-gut-enteric microbiota axis</article-title>. <source/>Nat Rev Gastroenterol Hepatol. (<year>2009</year>) <volume>6</volume>:<fpage>306</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2009.35</pub-id><pub-id pub-id-type="pmid">19404271</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>FB</given-names></name><name><surname>Powley</surname><given-names>TL</given-names></name></person-group>. <article-title>Vagal innervation of intestines: afferent pathways mapped with new en bloc horseradish peroxidase adaptation</article-title>. <source/>Cell Tissue Res. (<year>2007</year>) <volume>329</volume>:<fpage>221</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-007-0413-7</pub-id><pub-id pub-id-type="pmid">17453246</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinninella</surname><given-names>E</given-names></name><name><surname>Raoul</surname><given-names>P</given-names></name><name><surname>Cintoni</surname><given-names>M</given-names></name><name><surname>Franceschi</surname><given-names>F</given-names></name><name><surname>Miggiano</surname><given-names>GAD</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases</article-title>. <source/>Microorganisms. (<year>2019</year>) <volume>7</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.3390/microorganisms7010014</pub-id><pub-id pub-id-type="pmid">30634578</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Raes</surname><given-names>J</given-names></name><name><surname>Arumugam</surname><given-names>M</given-names></name><name><surname>Burgdorf</surname><given-names>KS</given-names></name><name><surname>Manichanh</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>A human gut microbial gene catalogue established by metagenomic sequencing</article-title>. <source/>Nature. (<year>2010</year>) <volume>464</volume>:<fpage>59</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/nature08821</pub-id><pub-id pub-id-type="pmid">20203603</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>RJ</given-names></name><name><surname>Wong</surname><given-names>CHY</given-names></name></person-group>. <article-title>An insight into intestinal mucosal microbiota disruption after stroke</article-title>. <source/>Sci Rep. (<year>2018</year>) <volume>8</volume>:<fpage>568</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-18904-8</pub-id><pub-id pub-id-type="pmid">29330443</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanley</surname><given-names>D</given-names></name><name><surname>Mason</surname><given-names>LJ</given-names></name><name><surname>Mackin</surname><given-names>KE</given-names></name><name><surname>Srikhanta</surname><given-names>YN</given-names></name><name><surname>Lyras</surname><given-names>D</given-names></name><name><surname>Prakash</surname><given-names>MD</given-names></name><etal></etal></person-group>. <article-title>Translocation and dissemination of commensal bacteria in post-stroke infection</article-title>. <source/>Nat Med. (<year>2016</year>) <volume>22</volume>:<fpage>1277</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4194</pub-id><pub-id pub-id-type="pmid">27694934</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>LA</given-names></name><name><surname>Materna</surname><given-names>AC</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Campos-Baptista</surname><given-names>MI</given-names></name><name><surname>Blackburn</surname><given-names>MC</given-names></name><name><surname>Perrotta</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Host lifestyle affects human microbiota on daily timescales</article-title>. <source/>Genome Biol. (<year>2014</year>) <volume>15</volume>:<fpage>R89</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2014-15-7-r89</pub-id><pub-id pub-id-type="pmid">25146375</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urra</surname><given-names>X</given-names></name><name><surname>Laredo</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Amaro</surname><given-names>S</given-names></name><name><surname>Rudilosso</surname><given-names>S</given-names></name><name><surname>Renú</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Neuroanatomical correlates of stroke-associated infection and stroke-induced immunodepression</article-title>. <source/>Brain Behav Immun. (<year>2017</year>) <volume>60</volume>:<fpage>142</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.10.004</pub-id><pub-id pub-id-type="pmid">27742582</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furness</surname><given-names>JB</given-names></name><name><surname>Callaghan</surname><given-names>BP</given-names></name><name><surname>Rivera</surname><given-names>LR</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name></person-group>. <article-title>The enteric nervous system and gastrointestinal innervation: integrated local and central control</article-title>. <source/>Adv Exp Med Biol. (<year>2014</year>) <volume>817</volume>:<fpage>39</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-0897-4_3</pub-id><pub-id pub-id-type="pmid">24997029</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyland</surname><given-names>NP</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name></person-group>. <article-title>Microbe-host interactions: influence of the gut microbiota on the enteric nervous system</article-title>. <source/>Dev Biol. (<year>2016</year>) <volume>417</volume>:<fpage>182</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ydbio.2016.06.027</pub-id><pub-id pub-id-type="pmid">27343895</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frederiksen</surname><given-names>HR</given-names></name><name><surname>Haukedal</surname><given-names>H</given-names></name><name><surname>Freude</surname><given-names>K</given-names></name></person-group>. <article-title>Cell type specific expression of toll-Like receptors in human brains and implications in alzheimer's disease</article-title>. <source/>Biomed Res Int. (<year>2019</year>) <volume>2019</volume>:<fpage>7420189</fpage>. <pub-id pub-id-type="doi">10.1155/2019/7420189</pub-id><pub-id pub-id-type="pmid">31396533</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Atorvastatin attenuates cognitive deficits and neuroinflammation induced by aβ1-42 involving modulation of tLR4/TRAF6/NF-κB pathway</article-title>. <source/>J Mol Neurosci. (<year>2018</year>) <volume>64</volume>:<fpage>363</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-018-1032-3</pub-id><pub-id pub-id-type="pmid">29417448</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>The progress of gut microbiome research related to brain disorders</article-title>. <source/>J Neuroinflammation. (<year>2020</year>) <volume>17</volume>:<fpage>1</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1186/s12974-020-1705-z</pub-id><pub-id pub-id-type="pmid">31900165</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Volchkov</surname><given-names>PY</given-names></name><name><surname>Stranges</surname><given-names>PB</given-names></name><name><surname>Avanesyan</surname><given-names>L</given-names></name><name><surname>Stonebraker</surname><given-names>AC</given-names></name><etal></etal></person-group>. <article-title>Innate immunity and intestinal microbiota in the development of type 1 diabetes</article-title>. <source/>Nature. (<year>2008</year>) <volume>455</volume>:<fpage>1109</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/nature07336</pub-id><pub-id pub-id-type="pmid">18806780</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubeda</surname><given-names>C</given-names></name><name><surname>Lipuma</surname><given-names>L</given-names></name><name><surname>Gobourne</surname><given-names>A</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Leiner</surname><given-names>I</given-names></name><name><surname>Equinda</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of tLR-deficient mice</article-title>. <source/>J Exp Med. (<year>2012</year>) <volume>209</volume>:<fpage>1445</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20120504</pub-id><pub-id pub-id-type="pmid">22826298</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouskra</surname><given-names>D</given-names></name><name><surname>Brézillon</surname><given-names>C</given-names></name><name><surname>Bérard</surname><given-names>M</given-names></name><name><surname>Werts</surname><given-names>C</given-names></name><name><surname>Varona</surname><given-names>R</given-names></name><name><surname>Boneca</surname><given-names>IG</given-names></name><etal></etal></person-group>. <article-title>Lymphoid tissue genesis induced by commensals through nOD1 regulates intestinal homeostasis</article-title>. <source/>Nature. (<year>2008</year>) <volume>456</volume>:<fpage>507</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/nature07450</pub-id><pub-id pub-id-type="pmid">18987631</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couturier-Maillard</surname><given-names>A</given-names></name><name><surname>Secher</surname><given-names>T</given-names></name><name><surname>Rehman</surname><given-names>A</given-names></name><name><surname>Normand</surname><given-names>S</given-names></name><name><surname>De Arcangelis</surname><given-names>A</given-names></name><name><surname>Haesler</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer</article-title>. <source/>J Clin Invest. (<year>2013</year>) <volume>123</volume>:<fpage>700</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1172/JCI62236</pub-id><pub-id pub-id-type="pmid">23281400</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Kolodziejczyk</surname><given-names>AA</given-names></name><name><surname>Thaiss</surname><given-names>CA</given-names></name><name><surname>Elinav</surname><given-names>E</given-names></name></person-group>
<article-title>Dysbiosis and the immune system</article-title>. <source/>Nat Rev Immunol. (<year>2017</year>) <volume>17</volume>:<fpage>219</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.7</pub-id><pub-id pub-id-type="pmid">28260787</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao-Mejia</surname><given-names>J</given-names></name><name><surname>Elinav</surname><given-names>E</given-names></name><name><surname>Thaiss</surname><given-names>CA</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group>. <article-title>Inflammasomes and metabolic disease</article-title>. <source/>Annu Rev Physiol. (<year>2014</year>) <volume>76</volume>:<fpage>57</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-physiol-021113-170324</pub-id><pub-id pub-id-type="pmid">24274736</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>TH</given-names></name><name><surname>Maruya</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Tsutsui</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Microbial exposure during early life has persistent effects on natural killer t Cell function</article-title>. <source/>Science. (<year>2012</year>) <volume>336</volume>:<fpage>485</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.1217718</pub-id><pub-id pub-id-type="pmid">22539724</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampron</surname><given-names>A</given-names></name><name><surname>Pimentel-Coelho</surname><given-names>PM</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group>. <article-title>Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration</article-title>. <source/>J Comp Neurol. (<year>2013</year>) <volume>521</volume>:<fpage>3863</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1002/cne.23363</pub-id><pub-id pub-id-type="pmid">23682015</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>KP</given-names></name><name><surname>Stanley</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>RJ</given-names></name><name><surname>Hao Van</surname><given-names>TT</given-names></name><name><surname>Wen</surname><given-names>SW</given-names></name><etal></etal></person-group>. <article-title>Invariant natural killer t cells shape the gut microbiota and regulate neutrophil recruitment and function during intestinal inflammation</article-title>. <source/>Front Immunol. (<year>2018</year>) <volume>9</volume>:<fpage>999</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00999</pub-id><pub-id pub-id-type="pmid">29867976</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>C</given-names></name><name><surname>Blume</surname><given-names>J</given-names></name><name><surname>Roy</surname><given-names>U</given-names></name><name><surname>Teh</surname><given-names>PP</given-names></name><name><surname>Vasanthakumar</surname><given-names>A</given-names></name><name><surname>Beller</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>c-Maf-dependent treg cell control of intestinal tH17 cells and igA establishes host-microbiota homeostasis</article-title>. <source/>Nat Immunol. (<year>2019</year>) <volume>20</volume>:<fpage>471</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-019-0316-2</pub-id><pub-id pub-id-type="pmid">30778241</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berer</surname><given-names>K</given-names></name><name><surname>Mues</surname><given-names>M</given-names></name><name><surname>Koutrolos</surname><given-names>M</given-names></name><name><surname>AlRasbi</surname><given-names>Z</given-names></name><name><surname>Boziki</surname><given-names>M</given-names></name><name><surname>Johner</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination</article-title>. <source/>Nature. (<year>2011</year>) <volume>479</volume>:<fpage>538</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/nature10554</pub-id><pub-id pub-id-type="pmid">22031325</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erny</surname><given-names>D</given-names></name><name><surname>De Angelis</surname><given-names>ALH</given-names></name><name><surname>Jaitin</surname><given-names>D</given-names></name><name><surname>Wieghofer</surname><given-names>P</given-names></name><name><surname>Staszewski</surname><given-names>O</given-names></name><name><surname>David</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Host microbiota constantly control maturation and function of microglia in the cNS</article-title>. <source/>Nat Neurosci. (<year>2015</year>) <volume>18</volume>:<fpage>965</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4030</pub-id><pub-id pub-id-type="pmid">26030851</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braniste</surname><given-names>V</given-names></name><name><surname>Al-Asmakh</surname><given-names>M</given-names></name><name><surname>Kowal</surname><given-names>C</given-names></name><name><surname>Anuar</surname><given-names>F</given-names></name><name><surname>Abbaspour</surname><given-names>A</given-names></name><name><surname>Tóth</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>The gut microbiota influences blood-brain barrier permeability in mice</article-title>. <source/>Sci Transl Med. (<year>2014</year>) <volume>6</volume>:<fpage>263ra158</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3009759</pub-id><pub-id pub-id-type="pmid">25411471</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><etal></etal></person-group>. <article-title>Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death</article-title>. <source/>Crit Care. (<year>2019</year>) <volume>23</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-019-2488-4</pub-id><pub-id pub-id-type="pmid">30621748</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>HX</given-names></name><name><surname>Kim</surname><given-names>HA</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Chan</surname><given-names>CT</given-names></name><name><surname>Vinh</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Immune cell infiltration in malignant middle cerebral artery infarction: comparison with transient cerebral ischemia</article-title>. <source/>J Cereb Blood Flow Metab. (<year>2014</year>) <volume>34</volume>:<fpage>450</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2013.217</pub-id><pub-id pub-id-type="pmid">24326388</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronenberg</surname><given-names>G</given-names></name><name><surname>Uhlemann</surname><given-names>R</given-names></name><name><surname>Richter</surname><given-names>N</given-names></name><name><surname>Klempin</surname><given-names>F</given-names></name><name><surname>Wegner</surname><given-names>S</given-names></name><name><surname>Staerck</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Distinguishing features of microglia- and monocyte-derived macrophages after stroke</article-title>. <source/>Acta Neuropathol. (<year>2018</year>) <volume>135</volume>:<fpage>551</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-017-1795-6</pub-id><pub-id pub-id-type="pmid">29249001</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattananit</surname><given-names>S</given-names></name><name><surname>Tornero</surname><given-names>D</given-names></name><name><surname>Graubardt</surname><given-names>N</given-names></name><name><surname>Memanishvili</surname><given-names>T</given-names></name><name><surname>Monni</surname><given-names>E</given-names></name><name><surname>Tatarishvili</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Monocyte-derived macrophages contribute to spontaneous long-Term functional recovery after stroke in mice</article-title>. <source/>J Neurosci. (<year>2016</year>) <volume>36</volume>:<fpage>4182</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4317-15.2016</pub-id><pub-id pub-id-type="pmid">27076418</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaud</surname><given-names>JP</given-names></name><name><surname>Pimentel-Coelho</surname><given-names>PM</given-names></name><name><surname>Tremblay</surname><given-names>Y</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name></person-group>. <article-title>The impact of ly6C low monocytes after cerebral hypoxia-ischemia in adult mice</article-title>. <source/>J Cereb Blood Flow Metab. (<year>2014</year>) <volume>34</volume>:<fpage>80</fpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2014.80</pub-id><pub-id pub-id-type="pmid">24780898</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anrather</surname><given-names>J</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group>. <article-title>Inflammation and stroke: an overview</article-title>. <source/>Neurotherapeutics. (<year>2016</year>) <volume>13</volume>:<fpage>661</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-016-0483-x</pub-id><pub-id pub-id-type="pmid">27730544</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuartero</surname><given-names>MI</given-names></name><name><surname>Ballesteros</surname><given-names>I</given-names></name><name><surname>Moraga</surname><given-names>A</given-names></name><name><surname>Nombela</surname><given-names>F</given-names></name><name><surname>Vivancos</surname><given-names>J</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>N2 neutrophils, novel players in brain inflammation after stroke: modulation by the pPARγ agonist rosiglitazone</article-title>. <source/>Stroke. (<year>2013</year>) <volume>44</volume>:<fpage>3498</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.113.002470</pub-id><pub-id pub-id-type="pmid">24135932</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Johnson</surname><given-names>EM</given-names></name><name><surname>Lam</surname><given-names>RK</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Bo Ye</surname><given-names>H</given-names></name><name><surname>Wilson</surname><given-names>EN</given-names></name><etal></etal></person-group>. <article-title>Peripheral tREM1 responses to brain and intestinal immunogens amplify stroke severity</article-title>. <source/>Nat Immunol. (<year>2019</year>) <volume>20</volume>:<fpage>1023</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-019-0421-2</pub-id><pub-id pub-id-type="pmid">31263278</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarkson</surname><given-names>BDS</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Harris</surname><given-names>MG</given-names></name><name><surname>Rayasam</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice</article-title>. <source/>J Exp Med. (<year>2014</year>) <volume>211</volume>:<fpage>595</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20131377</pub-id><pub-id pub-id-type="pmid">24616379</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelderblom</surname><given-names>M</given-names></name><name><surname>Arunachalam</surname><given-names>P</given-names></name><name><surname>Magnus</surname><given-names>T</given-names></name></person-group>. <article-title>γδ T cells as early sensors of tissue damage and mediators of secondary neurodegeneration</article-title>. <source/>Front Cell Neurosci. (<year>2014</year>) <volume>8</volume>:<fpage>368</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00368</pub-id><pub-id pub-id-type="pmid">25414640</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelderblom</surname><given-names>M</given-names></name><name><surname>Weymar</surname><given-names>A</given-names></name><name><surname>Bernreuther</surname><given-names>C</given-names></name><name><surname>Velden</surname><given-names>J</given-names></name><name><surname>Arunachalam</surname><given-names>P</given-names></name><name><surname>Steinbach</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Neutralization of the iL-17 axis diminishes neutrophil invasion and protects from ischemic stroke</article-title>. <source/>Blood. (<year>2012</year>) <volume>120</volume>:<fpage>3793</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-02-412726</pub-id><pub-id pub-id-type="pmid">22976954</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veltkamp</surname><given-names>R</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name></person-group>. <article-title>Clinical trials of immunomodulation in ischemic stroke</article-title>. <source/>Neurotherapeutics. (<year>2016</year>) <volume>13</volume>:<fpage>791</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-016-0458-y</pub-id><pub-id pub-id-type="pmid">27412685</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Sadler</surname><given-names>R</given-names></name><name><surname>Heindl</surname><given-names>S</given-names></name><name><surname>Llovera</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>S</given-names></name><name><surname>Benakis</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>The gut microbiome primes a cerebroprotective immune response after stroke</article-title>. <source/>J Cereb Blood Flow Metab. (<year>2018</year>) <volume>38</volume>:<fpage>1293</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X18780130</pub-id><pub-id pub-id-type="pmid">29846130</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Dreykluft</surname><given-names>A</given-names></name><name><surname>Hagedorn</surname><given-names>I</given-names></name><name><surname>Göbel</surname><given-names>K</given-names></name><name><surname>Schuhmann</surname><given-names>MK</given-names></name><etal></etal></person-group>. <article-title>Regulatory t cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature</article-title>. <source/>Blood. (<year>2013</year>) <volume>121</volume>:<fpage>679</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2012-04-426734</pub-id><pub-id pub-id-type="pmid">23160472</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Persistence of gut microbiota dysbiosis and chronic systemic inflammation after cerebral infarction in cynomolgus monkeys</article-title>. <source/>Front Neurol. (<year>2019</year>) <volume>10</volume>:<fpage>661</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2019.00661</pub-id><pub-id pub-id-type="pmid">31316450</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Roth</surname><given-names>S</given-names></name><name><surname>Llovera</surname><given-names>G</given-names></name><name><surname>Sadler</surname><given-names>R</given-names></name><name><surname>Garzetti</surname><given-names>D</given-names></name><name><surname>Stecher</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Microbiota dysbiosis controls the neuroinflammatory response after stroke</article-title>. <source/>J Neurosci. (<year>2016</year>) <volume>36</volume>:<fpage>7428</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1114-16.2016</pub-id><pub-id pub-id-type="pmid">27413153</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeij</surname><given-names>FH</given-names></name><name><surname>Scholte</surname><given-names>OP</given-names></name><name><surname>Reimer</surname><given-names>WJM</given-names></name><name><surname>De Man</surname><given-names>P</given-names></name><name><surname>Van Oostenbrugge</surname><given-names>RJ</given-names></name><name><surname>Franke</surname><given-names>CL</given-names></name><etal></etal></person-group>. <article-title>Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey</article-title>. <source/>Cerebrovasc Dis. (<year>2009</year>) <volume>27</volume>:<fpage>465</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1159/000210093</pub-id><pub-id pub-id-type="pmid">19329851</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukiw</surname><given-names>WJ</given-names></name><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Jaber</surname><given-names>V</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group>. <article-title>Microbiome-Derived lipopolysaccharide (LPS) selectively inhibits neurofilament light chain (NF-L) gene expression in human neuronal-Glial (HNG) cells in primary culture</article-title>. <source/>Front Neurosci. (<year>2018</year>) <volume>12</volume>:<fpage>896</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2018.00896</pub-id><pub-id pub-id-type="pmid">30568571</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>GH</given-names></name><name><surname>You</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>XX</given-names></name><name><surname>Zeng</surname><given-names>XL</given-names></name><name><surname>Zhu</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>KY</given-names></name><etal></etal></person-group>. <article-title>Stroke dysbiosis index (SDI) in gut microbiome are associated with brain injury and prognosis of stroke</article-title>. <source/>Front Neurol. (<year>2019</year>) <volume>10</volume>:<fpage>397</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2019.00397</pub-id><pub-id pub-id-type="pmid">31068891</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>SX</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>GH</given-names></name><name><surname>Liu</surname><given-names>FT</given-names></name><etal></etal></person-group>
<article-title>Dysbiosis of gut microbiota with reduced trimethylamine-n-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack</article-title>. <source/>J Am Hear Assoc. (<year>2015</year>) <volume>4</volume>:<fpage>e002699</fpage>
<pub-id pub-id-type="doi">10.1161/JAHA.115.002699</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Weng</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Change of intestinal microbiota in cerebral ischemic stroke patients</article-title>. <source/>BMC Microbiol. (<year>2019</year>) <volume>19</volume>:<fpage>191</fpage>. <pub-id pub-id-type="doi">10.1186/s12866-019-1552-1</pub-id><pub-id pub-id-type="pmid">31426765</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C</given-names></name><name><surname>Murdock</surname><given-names>MH</given-names></name><name><surname>Jing</surname><given-names>D</given-names></name><name><surname>Won</surname><given-names>TH</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Kressel</surname><given-names>AM</given-names></name><etal></etal></person-group>. <article-title>The microbiota regulate neuronal function and fear extinction learning</article-title>. <source/>Nature. (<year>2019</year>) <volume>574</volume>:<fpage>543</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1644-y</pub-id><pub-id pub-id-type="pmid">31645720</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashiro</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>R</given-names></name><name><surname>Urabe</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>Y</given-names></name><name><surname>Yamashiro</surname><given-names>Y</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke</article-title>. <source/>PLoS ONE. (<year>2017</year>) <volume>12</volume>:<fpage>e0171521</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0171521</pub-id><pub-id pub-id-type="pmid">28166278</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonsack</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>RHY</given-names></name><name><surname>Borlongan</surname><given-names>C V</given-names></name></person-group>. <article-title>A gut feeling about stroke reveals gut-brain axis' active role in homeostasis and dysbiosis</article-title>. <source/>J Cereb Blood Flow Metab. (<year>2020</year>) <volume>40</volume>:<fpage>1132</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X19900037</pub-id><pub-id pub-id-type="pmid">32063084</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Higher risk of stroke is correlated with increased opportunistic pathogen load and reduced levels of butyrate-Producing bacteria in the gut</article-title>. <source/>Front Cell Infect Microbiol. (<year>2019</year>) <volume>9</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2019.00004</pub-id><pub-id pub-id-type="pmid">30778376</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adnan</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>JW</given-names></name><name><surname>Ajami</surname><given-names>NJ</given-names></name><name><surname>Venna</surname><given-names>VR</given-names></name><name><surname>Petrosino</surname><given-names>JF</given-names></name><name><surname>Bryan</surname><given-names>RM</given-names></name><etal></etal></person-group>. <article-title>Alterations in the gut microbiota can elicit hypertension in rats</article-title>. <source/>Physiol Genomics. (<year>2017</year>) <volume>49</volume>:<fpage>96</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1152/physiolgenomics.00081.2016</pub-id><pub-id pub-id-type="pmid">28011881</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avolio</surname><given-names>E</given-names></name><name><surname>Gualtieri</surname><given-names>P</given-names></name><name><surname>Romano</surname><given-names>L</given-names></name><name><surname>Pecorella</surname><given-names>C</given-names></name><name><surname>Ferraro</surname><given-names>S</given-names></name><name><surname>Palma</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Obesity and body composition in man and woman: associated diseases and the new role of gut microbiota</article-title>. <source/>Curr Med Chem. (<year>2019</year>) <volume>27</volume>:<fpage>216</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.2174/0929867326666190326113607</pub-id><pub-id pub-id-type="pmid">30914014</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdecchia</surname><given-names>P</given-names></name><name><surname>Porcellati</surname><given-names>C</given-names></name><name><surname>Reboldi</surname><given-names>G</given-names></name><name><surname>Gattobigio</surname><given-names>R</given-names></name><name><surname>Borgioni</surname><given-names>C</given-names></name><name><surname>Pearson</surname><given-names>TA</given-names></name><etal></etal></person-group>. <article-title>Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension</article-title>. <source/>Circulation. (<year>2001</year>) <volume>104</volume>:<fpage>2039</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1161/hc4201.097944</pub-id><pub-id pub-id-type="pmid">11673343</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>K</given-names></name></person-group>. <article-title>Traumatic brain injury: pathophysiology for neurocritical care</article-title>. <source/>J Intensive Care. (<year>2016</year>) <volume>4</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/s40560-016-0138-3</pub-id><pub-id pub-id-type="pmid">26753096</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>SB</given-names></name><name><surname>Yoon</surname><given-names>BW</given-names></name></person-group>. <article-title>Blood pressure management for acute ischemic and hemorrhagic stroke: the evidence</article-title>. <source/>Semin Respir Crit Care Med. (<year>2017</year>) <volume>38</volume>:<fpage>718</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1055/s-0037-1608777</pub-id><pub-id pub-id-type="pmid">29262429</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forouzanfar</surname><given-names>MH</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Ng</surname><given-names>M</given-names></name><name><surname>Biryukov</surname><given-names>S</given-names></name><name><surname>Marczak</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015</article-title>. <source/>JAMA. (<year>2017</year>) <volume>317</volume>:<fpage>165</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2016.19043</pub-id><pub-id pub-id-type="pmid">28097354</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leustean</surname><given-names>AM</given-names></name><name><surname>Ciocoiu</surname><given-names>M</given-names></name><name><surname>Sava</surname><given-names>A</given-names></name><name><surname>Costea</surname><given-names>CF</given-names></name><name><surname>Floria</surname><given-names>M</given-names></name><name><surname>Tarniceriu</surname><given-names>CC</given-names></name><etal></etal></person-group>. <article-title>Implications of the intestinal microbiota in diagnosing the progression of diabetes and the presence of cardiovascular complications</article-title>. <source/>J Diabetes Res. (<year>2018</year>) <volume>2018</volume>:<fpage>5205126</fpage>. <pub-id pub-id-type="doi">10.1155/2018/5205126</pub-id><pub-id pub-id-type="pmid">30539026</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winther</surname><given-names>SA</given-names></name><name><surname>Øllgaard</surname><given-names>JC</given-names></name><name><surname>Tofte</surname><given-names>N</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ahluwalia</surname><given-names>TS</given-names></name><name><surname>Jorsal</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Utility of plasma concentration of trimethylamine n-oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes</article-title>. <source/>Diabetes Care. (<year>2019</year>) <volume>42</volume>:<fpage>1512</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.2337/dc19-0048</pub-id><pub-id pub-id-type="pmid">31123156</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Dynamic changes and prognostic value of gut microbiota-Dependent trimethylamine-N-Oxide in acute ischemic stroke</article-title>. <source/>Front Neurol. (<year>2020</year>) <volume>11</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2020.00029</pub-id><pub-id pub-id-type="pmid">32082246</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Santisteban</surname><given-names>MM</given-names></name><name><surname>Rodriguez</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Ahmari</surname><given-names>N</given-names></name><name><surname>Carvajal</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Gut dysbiosis is linked to hypertension novelty and significance</article-title>. <source/>Hypertension. (<year>2015</year>) <volume>65</volume>:<fpage>1331</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.05315</pub-id><pub-id pub-id-type="pmid">25870193</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westendorp</surname><given-names>WF</given-names></name><name><surname>Nederkoorn</surname><given-names>PJ</given-names></name><name><surname>Vermeij</surname><given-names>JD</given-names></name><name><surname>Dijkgraaf</surname><given-names>MG</given-names></name><name><surname>van de Beek</surname><given-names>D</given-names></name></person-group>. <article-title>Post-stroke infection: a systematic review and meta-analysis</article-title>. <source/>BMC Neurol. (<year>2011</year>) <volume>11</volume>:<fpage>110</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2377-11-110</pub-id><pub-id pub-id-type="pmid">21933425</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeij</surname><given-names>JD</given-names></name><name><surname>Westendorp</surname><given-names>WF</given-names></name><name><surname>van de Beek</surname><given-names>D</given-names></name><name><surname>Nederkoorn</surname><given-names>PJ</given-names></name></person-group>. <article-title>Post-stroke infections and preventive antibiotics in stroke: update of clinical evidence</article-title>. <source/>Int J Stroke. (<year>2018</year>) <volume>13</volume>:<fpage>913</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1177/1747493018798557</pub-id><pub-id pub-id-type="pmid">30175940</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>R</given-names></name><name><surname>Foley</surname><given-names>N</given-names></name><name><surname>Bhogal</surname><given-names>S</given-names></name><name><surname>Diamant</surname><given-names>N</given-names></name><name><surname>Speechley</surname><given-names>M</given-names></name><name><surname>Teasell</surname><given-names>R</given-names></name></person-group>. <article-title>Dysphagia after stroke: incidence, diagnosis, and pulmonary complications</article-title>. <source/>Stroke. (<year>2005</year>) <volume>36</volume>:<fpage>2756</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000190056.76543.eb</pub-id><pub-id pub-id-type="pmid">16269630</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannawi</surname><given-names>Y</given-names></name><name><surname>Hannawi</surname><given-names>B</given-names></name><name><surname>Rao</surname><given-names>CPV</given-names></name><name><surname>Suarez</surname><given-names>JI</given-names></name><name><surname>Bershad</surname><given-names>EM</given-names></name></person-group>. <article-title>Stroke-Associated pneumonia: major advances and obstacles stroke-Associated pneumonia</article-title>. <source/>Cerebrovasc Dis. (<year>2013</year>) <volume>35</volume>:<fpage>430</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1159/000350199</pub-id><pub-id pub-id-type="pmid">23735757</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulm</surname><given-names>L</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Nabavi</surname><given-names>D</given-names></name><name><surname>Hermans</surname><given-names>M</given-names></name><name><surname>Mackert</surname><given-names>BM</given-names></name><name><surname>Hamilton</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>The randomized controlled sTRAWINSKI trial: procalcitonin-Guided antibiotic therapy after stroke</article-title>. <source/>Front Neurol. (<year>2017</year>) <volume>8</volume>:<fpage>153</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2017.00153</pub-id><pub-id pub-id-type="pmid">28484421</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prass</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>JS</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Meisel</surname><given-names>C</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name></person-group>. <article-title>Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia</article-title>. <source/>Stroke. (<year>2006</year>) <volume>37</volume>:<fpage>2607</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000240409.68739.2b</pub-id><pub-id pub-id-type="pmid">16946159</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battaglini</surname><given-names>D</given-names></name><name><surname>Robba</surname><given-names>C</given-names></name><name><surname>Lopes da Silva</surname><given-names>A</given-names></name><name><surname>dos Santos Samary</surname><given-names>C</given-names></name><name><surname>Leme Silva</surname><given-names>P</given-names></name><name><surname>Dal Pizzol</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Brain-heart interaction after acute ischemic stroke</article-title>. <source/>Crit Care. (<year>2020</year>) <volume>24</volume>:<fpage>163</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-02885-8</pub-id><pub-id pub-id-type="pmid">32317013</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavy</surname><given-names>S</given-names></name><name><surname>Yaar</surname><given-names>I</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name><name><surname>Stern</surname><given-names>S</given-names></name></person-group>. <article-title>The effect of acute stroke on cardiac functions as observed in an intensive stroke care unit</article-title>. <source/>Stroke. (<year>1974</year>) <volume>5</volume>:<fpage>775</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.5.6.775</pub-id><pub-id pub-id-type="pmid">4432256</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simula</surname><given-names>S</given-names></name><name><surname>Muuronen</surname><given-names>AT</given-names></name><name><surname>Taina</surname><given-names>M</given-names></name><name><surname>Jäkälä</surname><given-names>P</given-names></name><name><surname>Sipola</surname><given-names>P</given-names></name><name><surname>Vanninen</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Effect of middle cerebral artery territory ischemic stroke on qT interval</article-title>. <source/>J Stroke Cerebrovasc Dis. (<year>2014</year>) <volume>23</volume>:<fpage>717</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2013.06.032</pub-id><pub-id pub-id-type="pmid">24045085</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battson</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>DM</given-names></name><name><surname>Weir</surname><given-names>TL</given-names></name><name><surname>Gentile</surname><given-names>CL</given-names></name></person-group>. <article-title>The gut microbiota as a novel regulator of cardiovascular function and disease</article-title>. <source/>J Nutr Biochem. (<year>2018</year>) <volume>56</volume>:<fpage>1</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2017.12.010</pub-id><pub-id pub-id-type="pmid">29427903</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Lian</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Elevated trimethylamine n-oxide related to ischemic brain lesions after carotid artery stenting</article-title>. <source/>Neurology. (<year>2018</year>) <volume>90</volume>:<fpage>e1283</fpage>–<lpage>e90</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000005298</pub-id><pub-id pub-id-type="pmid">29540587</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>Koeth</surname><given-names>RA</given-names></name><name><surname>Britt</surname><given-names>EB</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk</article-title>. <source/>N Engl J Med. (<year>2013</year>) <volume>368</volume>:<fpage>1575</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1109400</pub-id><pub-id pub-id-type="pmid">23614584</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>JR</given-names></name><name><surname>Kennedy</surname><given-names>PJ</given-names></name><name><surname>Cryan</surname><given-names>JF</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name><name><surname>Clarke</surname><given-names>G</given-names></name><name><surname>Hyland</surname><given-names>NP</given-names></name></person-group>. <article-title>Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders</article-title>. <source/>Front Cell Neurosci. (<year>2015</year>) <volume>9</volume>:<fpage>392</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00392</pub-id><pub-id pub-id-type="pmid">26528128</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winek</surname><given-names>K</given-names></name><name><surname>Engel</surname><given-names>O</given-names></name><name><surname>Koduah</surname><given-names>P</given-names></name><name><surname>Heimesaat</surname><given-names>MM</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Bereswill</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Depletion of cultivatable gut microbiota by broad-Spectrum antibiotic pretreatment worsens outcome after murine stroke</article-title>. <source/>Stroke. (<year>2016</year>) <volume>47</volume>:<fpage>1354</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.115.011800</pub-id><pub-id pub-id-type="pmid">27056982</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durgan</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>McCullough</surname><given-names>LD</given-names></name><name><surname>Bryan</surname><given-names>RM</given-names></name></person-group>. <article-title>Examining the role of the microbiota-Gut-Brain axis in stroke</article-title>. <source/>Stroke. (<year>2019</year>) <volume>50</volume>:<fpage>2270</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.119.025140</pub-id><pub-id pub-id-type="pmid">31272315</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>YL</given-names></name><name><surname>Chou</surname><given-names>CC</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name><name><surname>Hsu</surname><given-names>JL</given-names></name><etal></etal></person-group>. <article-title>Increased risk of stroke among patients with crohn's disease: a population-based matched cohort study</article-title>. <source/>Int J Colorectal Dis. (<year>2015</year>) <volume>30</volume>:<fpage>645</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s00384-015-2132-y</pub-id><pub-id pub-id-type="pmid">25608496</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>KS</given-names></name><name><surname>Zakai</surname><given-names>NA</given-names></name><name><surname>Lidofsky</surname><given-names>SD</given-names></name><name><surname>Callas</surname><given-names>PW</given-names></name><name><surname>Judd</surname><given-names>SE</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><etal></etal></person-group>. <article-title>Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: the reasons for geographic and racial differences in stroke cohort</article-title>. <source/>PLoS ONE. (<year>2018</year>) <volume>13</volume>:<fpage>e0194153</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0194153</pub-id><pub-id pub-id-type="pmid">29529073</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripodi</surname><given-names>A</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name></person-group>. <article-title>Liver disease coagulopathy</article-title>. <source/>N Engl J Med. (<year>2011</year>) <volume>365</volume>:<fpage>147</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1011170</pub-id><pub-id pub-id-type="pmid">21751907</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>NS</given-names></name><name><surname>Navi</surname><given-names>BB</given-names></name><name><surname>Schneider</surname><given-names>Y</given-names></name><name><surname>Jesudian</surname><given-names>A</given-names></name><name><surname>Kamel</surname><given-names>H</given-names></name></person-group>. <article-title>Association between cirrhosis and stroke in a nationally representative cohort</article-title>. <source/>JAMA Neurol. (<year>2017</year>) <volume>74</volume>:<fpage>927</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2017.0923</pub-id><pub-id pub-id-type="pmid">28586894</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Gregory</surname><given-names>JC</given-names></name><name><surname>Org</surname><given-names>E</given-names></name><name><surname>Buffa</surname><given-names>JA</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Gut microbial metabolite tMAO enhances platelet hyperreactivity and thrombosis risk</article-title>. <source/>Cell. (<year>2016</year>) <volume>165</volume>:<fpage>111</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.02.011</pub-id><pub-id pub-id-type="pmid">26972052</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velasquez</surname><given-names>MT</given-names></name><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Manal</surname><given-names>A</given-names></name><name><surname>Raj</surname><given-names>DS</given-names></name></person-group>. <article-title>Trimethylamine n-oxide: the good, the bad and the unknown</article-title>. <source/>Toxins. (<year>2016</year>) <volume>8</volume>:<fpage>26</fpage>. <pub-id pub-id-type="doi">10.3390/toxins8110326</pub-id><pub-id pub-id-type="pmid">27834801</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeth</surname><given-names>RA</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>Buffa</surname><given-names>JA</given-names></name><name><surname>Org</surname><given-names>E</given-names></name><name><surname>Sheehy</surname><given-names>BT</given-names></name><etal></etal></person-group>. <article-title>Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis</article-title>. <source/>Nat Med. (<year>2013</year>) <volume>19</volume>:<fpage>576</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3145</pub-id><pub-id pub-id-type="pmid">23563705</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoda</surname><given-names>K</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name></person-group>. <article-title>Stroke and cerebrovascular diseases in patients with chronic kidney disease</article-title>. <source/>Lancet Neurol. (<year>2014</year>) <volume>13</volume>:<fpage>823</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(14)70026-2</pub-id><pub-id pub-id-type="pmid">25030514</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>KP</given-names></name><name><surname>Sims</surname><given-names>D</given-names></name><name><surname>Gill</surname><given-names>P</given-names></name><name><surname>Cockwell</surname><given-names>P</given-names></name><name><surname>Ferro</surname><given-names>C</given-names></name></person-group>. <article-title>Incidence and impact on outcomes of acute kidney injury after a stroke: a systematic review and meta-analysis</article-title>. <source/>BMC Nephrol. (<year>2018</year>) <volume>19</volume>:<fpage>283</fpage>. <pub-id pub-id-type="doi">10.1186/s12882-018-1085-0</pub-id><pub-id pub-id-type="pmid">30348107</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumai</surname><given-names>Y</given-names></name><name><surname>Kamouchi</surname><given-names>M</given-names></name><name><surname>Hata</surname><given-names>J</given-names></name><name><surname>Ago</surname><given-names>T</given-names></name><name><surname>Kitayama</surname><given-names>J</given-names></name><name><surname>Nakane</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Proteinuria and clinical outcomes after ischemic stroke</article-title>. <source/>Neurology. (<year>2012</year>) <volume>78</volume>:<fpage>1909</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e318259e110</pub-id><pub-id pub-id-type="pmid">22592359</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onal</surname><given-names>EM</given-names></name><name><surname>Afsar</surname><given-names>B</given-names></name><name><surname>Covic</surname><given-names>A</given-names></name><name><surname>Vaziri</surname><given-names>ND</given-names></name><name><surname>Kanbay</surname><given-names>M</given-names></name></person-group>. <article-title>Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease</article-title>. <source/>Hypertens Res. (<year>2019</year>) <volume>42</volume>:<fpage>123</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/s41440-018-0144-z</pub-id><pub-id pub-id-type="pmid">30504819</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hénaut</surname><given-names>L</given-names></name><name><surname>Grissi</surname><given-names>M</given-names></name><name><surname>Brazier</surname><given-names>F</given-names></name><name><surname>Assem</surname><given-names>M</given-names></name><name><surname>Poirot-Leclercq</surname><given-names>S</given-names></name><name><surname>Lenglet</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Cellular and molecular mechanisms associated with ischemic stroke severity in female mice with chronic kidney disease</article-title>. <source/>Sci Rep. (<year>2019</year>) <volume>9</volume>:<fpage>6432</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-42933-0</pub-id><pub-id pub-id-type="pmid">31015533</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>CE</given-names></name><name><surname>Caudill</surname><given-names>MA</given-names></name></person-group>. <article-title>Trimethylamine-N-Oxide: friend, foe, or simply caught in the cross-Fire?</article-title>
<source/>Trends Endocrinol Metab. (<year>2017</year>) <volume>28</volume>:<fpage>121</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2016.10.005</pub-id><pub-id pub-id-type="pmid">27825547</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kennedy</surname><given-names>DJ</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Buffa</surname><given-names>JA</given-names></name><name><surname>Agatisa-Boyle</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Gut microbiota-dependent trimethylamine n-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease</article-title>. <source/>Circ Res. (<year>2015</year>) <volume>116</volume>:<fpage>448</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305360</pub-id><pub-id pub-id-type="pmid">25599331</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahluwalia</surname><given-names>B</given-names></name><name><surname>Magnusson</surname><given-names>MK</given-names></name><name><surname>Öhman</surname><given-names>L</given-names></name></person-group>. <article-title>Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad</article-title>. <source/>Scand J Gastroenterol. (<year>2017</year>) <volume>52</volume>:<fpage>1185</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1080/00365521.2017.1349173</pub-id><pub-id pub-id-type="pmid">28697651</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audebert</surname><given-names>HJ</given-names></name><name><surname>Rott</surname><given-names>MM</given-names></name><name><surname>Eck</surname><given-names>T</given-names></name><name><surname>Haberl</surname><given-names>RL</given-names></name></person-group>. <article-title>Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis</article-title>. <source/>Stroke. (<year>2004</year>) <volume>35</volume>:<fpage>2128</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000137607.61697.77</pub-id><pub-id pub-id-type="pmid">15272127</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>HB</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>JX</given-names></name><name><surname>Song</surname><given-names>DB</given-names></name><name><surname>Tian</surname><given-names>JK</given-names></name></person-group>
<article-title>[Study on the clinical epidemiological features of acute cerebral stroke inducing systemic inflammatory response syndrome and multiple organ dysfunction syndrome]</article-title>. <source/>Zhonghua Liu Xing Bing Xue Za Zhi. (<year>2008</year>) <volume>29</volume>:<fpage>294</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">18788533</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Schieber</surname><given-names>AMP</given-names></name><name><surname>Redford</surname><given-names>SE</given-names></name><name><surname>Shokhirev</surname><given-names>MN</given-names></name><name><surname>Leblanc</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Cooperative metabolic adaptations in the host can favor asymptomatic infection and select for attenuated virulence in an enteric pathogen</article-title>. <source/>Cell. (<year>2018</year>) <volume>175</volume>:<fpage>146</fpage>–<lpage>58</lpage>.e15. <pub-id pub-id-type="doi">10.1016/j.cell.2018.07.016</pub-id><pub-id pub-id-type="pmid">30100182</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>JF</given-names></name><name><surname>Allayee</surname><given-names>H</given-names></name><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Ideraabdullah</surname><given-names>F</given-names></name><name><surname>Kris-Etherton</surname><given-names>PM</given-names></name><name><surname>Ordovás</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Nutrigenomics, the microbiome, and gene-environment interactions: new directions in cardiovascular disease research, prevention, and treatment: a Scientific statement from the american heart association</article-title>. <source/>Circ Cardiovasc Genet. (<year>2016</year>) <volume>9</volume>:<fpage>291</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1161/HCG.0000000000000030</pub-id><pub-id pub-id-type="pmid">27095829</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavaleri</surname><given-names>F</given-names></name><name><surname>Bashar</surname><given-names>E</given-names></name></person-group>. <article-title>Potential synergies of β -Hydroxybutyrate and butyrate on the modulation of metabolism, inflammation, cognition, and general health</article-title>. <source/>J Nutr Metab. (<year>2018</year>) <volume>2018</volume>:<fpage>1076</fpage>. <pub-id pub-id-type="doi">10.1155/2018/7195760</pub-id><pub-id pub-id-type="pmid">29805804</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutagy</surname><given-names>NE</given-names></name><name><surname>Neilson</surname><given-names>AP</given-names></name><name><surname>Osterberg</surname><given-names>KL</given-names></name><name><surname>Smithson</surname><given-names>AT</given-names></name><name><surname>Englund</surname><given-names>TR</given-names></name><name><surname>Davy</surname><given-names>BM</given-names></name><etal></etal></person-group>. <article-title>Short-term high-fat diet increases postprandial trimethylamine-N-oxide in humans</article-title>. <source/>Nutr Res. (<year>2015</year>) <volume>35</volume>:<fpage>858</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.nutres.2015.07.002</pub-id><pub-id pub-id-type="pmid">26265295</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aridi</surname><given-names>YS</given-names></name><name><surname>Walker</surname><given-names>JL</given-names></name><name><surname>Wright</surname><given-names>ORL</given-names></name></person-group>. <article-title>The association between the mediterranean dietary pattern and cognitive health: a systematic review</article-title>. <source/>Nutrients. (<year>2017</year>) <volume>9</volume>:<fpage>674</fpage>. <pub-id pub-id-type="doi">10.3390/nu9070674</pub-id><pub-id pub-id-type="pmid">28657600</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsivgoulis</surname><given-names>G</given-names></name><name><surname>Psaltopoulou</surname><given-names>T</given-names></name><name><surname>Wadley</surname><given-names>VG</given-names></name><name><surname>Alexandrov</surname><given-names>AV</given-names></name><name><surname>Howard</surname><given-names>G</given-names></name><name><surname>Unverzagt</surname><given-names>FW</given-names></name><etal></etal></person-group>. <article-title>Adherence to a mediterranean diet and prediction of incident stroke</article-title>. <source/>Stroke. (<year>2015</year>) <volume>46</volume>:<fpage>780</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.114.007894</pub-id><pub-id pub-id-type="pmid">25628306</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Mantrana</surname><given-names>I</given-names></name><name><surname>Selma-Royo</surname><given-names>M</given-names></name><name><surname>Alcantara</surname><given-names>C</given-names></name><name><surname>Collado</surname><given-names>MC</given-names></name></person-group>. <article-title>Shifts on gut microbiota associated to mediterranean diet adherence and specific dietary intakes on general adult population</article-title>. <source/>Front Microbiol. (<year>2018</year>) <volume>9</volume>:<fpage>890</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.00890</pub-id><pub-id pub-id-type="pmid">29867803</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>L</given-names></name><name><surname>Myrmel</surname><given-names>LS</given-names></name><name><surname>Fjære</surname><given-names>E</given-names></name><name><surname>Liaset</surname><given-names>B</given-names></name><name><surname>Kristiansen</surname><given-names>K</given-names></name></person-group>. <article-title>Links between dietary protein sources, the gut microbiota, and obesity</article-title>. <source/>Front Physiol. (<year>2017</year>) <volume>8</volume>:<fpage>1047</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2017.01047</pub-id><pub-id pub-id-type="pmid">29311977</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Pérez</surname><given-names>D</given-names></name><name><surname>Bressa</surname><given-names>C</given-names></name><name><surname>Bailén</surname><given-names>M</given-names></name><name><surname>Hamed-Bousdar</surname><given-names>S</given-names></name><name><surname>Naclerio</surname><given-names>F</given-names></name><name><surname>Carmona</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Effect of a protein supplement on the gut microbiota of endurance athletes: a Randomized, controlled, double-blind pilot study</article-title>. <source/>Nutrients. (<year>2018</year>) <volume>10</volume>:<fpage>337</fpage>. <pub-id pub-id-type="doi">10.3390/nu10030337</pub-id><pub-id pub-id-type="pmid">29534465</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venegas</surname><given-names>DP</given-names></name><name><surname>De La Fuente</surname><given-names>MK</given-names></name><name><surname>Landskron</surname><given-names>G</given-names></name><name><surname>González</surname><given-names>MJ</given-names></name><name><surname>Quera</surname><given-names>R</given-names></name><name><surname>Dijkstra</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Short chain fatty acids (SCFAs)mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases</article-title>. <source/>Front Immunol. (<year>2019</year>) <volume>10</volume>:<fpage>1486</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.01486</pub-id><pub-id pub-id-type="pmid">31316522</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadler</surname><given-names>R</given-names></name><name><surname>Cramer</surname><given-names>J V.</given-names></name><name><surname>Heindl</surname><given-names>S</given-names></name><name><surname>Kostidis</surname><given-names>S</given-names></name><name><surname>Betz</surname><given-names>D</given-names></name><name><surname>Zuurbier</surname><given-names>KR</given-names></name><etal></etal></person-group>. <article-title>Short-chain fatty acids improve poststroke recovery via immunological mechanisms</article-title>. <source/>J Neurosci. (<year>2020</year>) <volume>40</volume>:<fpage>1162</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1359-19.2019</pub-id><pub-id pub-id-type="pmid">31889008</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothari</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name></person-group>. <article-title>Probiotic supplements might not be universally-effective and safe: a review</article-title>. <source/>Biomed Pharmacother. (<year>2019</year>) <volume>111</volume>:<fpage>537</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.104</pub-id><pub-id pub-id-type="pmid">30597307</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowiak</surname><given-names>P</given-names></name><name><surname>Slizewska</surname><given-names>K</given-names></name></person-group>. <article-title>Effects of probiotics, prebiotics, and synbiotics on human health</article-title>. <source/>Nutrients. (<year>2017</year>) <volume>9</volume>:<fpage>1021</fpage>. <pub-id pub-id-type="doi">10.3390/nu9091021</pub-id><pub-id pub-id-type="pmid">28914794</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barraud</surname><given-names>D</given-names></name><name><surname>Bollaert</surname><given-names>PE</given-names></name><name><surname>Gibot</surname><given-names>S</given-names></name></person-group>. <article-title>Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials</article-title>. <source/>Chest. (<year>2013</year>) <volume>143</volume>:<fpage>646</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1378/chest.12-1745</pub-id><pub-id pub-id-type="pmid">23460153</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalra</surname><given-names>L</given-names></name><name><surname>Irshad</surname><given-names>S</given-names></name><name><surname>Hodsoll</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>M</given-names></name><name><surname>Gulliford</surname><given-names>M</given-names></name><name><surname>Smithard</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial</article-title>. <source/>Lancet. (<year>2015</year>) <volume>386</volume>:<fpage>1835</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)00126-9</pub-id><pub-id pub-id-type="pmid">26343840</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westendorp</surname><given-names>WF</given-names></name><name><surname>Vermeij</surname><given-names>J-D</given-names></name><name><surname>Zock</surname><given-names>E</given-names></name><name><surname>Hooijenga</surname><given-names>IJ</given-names></name><name><surname>Kruyt</surname><given-names>ND</given-names></name><name><surname>Bosboom</surname><given-names>HJLW</given-names></name><etal></etal></person-group>
<article-title>The preventive antibiotics in stroke study (PASS): a pragmatic randomised open-label masked endpoint clinical trial</article-title>. <source/>Lancet. (<year>2015</year>) <volume>385</volume>:<fpage>1519</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)62456-9</pub-id><pub-id pub-id-type="pmid">25612858</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KO</given-names></name><name><surname>Gluck</surname><given-names>M</given-names></name></person-group>. <article-title>Fecal microbiota transplantation: an update on clinical practice</article-title>. <source/>Clin Endosc. (<year>2019</year>) <volume>52</volume>:<fpage>137</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.5946/ce.2019.009</pub-id><pub-id pub-id-type="pmid">30909689</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evrensel</surname><given-names>A</given-names></name><name><surname>Ceylan</surname><given-names>ME</given-names></name></person-group>. <article-title>Fecal microbiota transplantation and its usage in neuropsychiatric disorders</article-title>. <source/>Clin Psychopharmacol Neurosci. (<year>2016</year>) <volume>14</volume>:<fpage>231</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.9758/cpn.2016.14.3.231</pub-id><pub-id pub-id-type="pmid">27489376</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lasanajak</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota</article-title>. <source/>Pharmacol Res. (<year>2019</year>) <volume>148</volume>:<fpage>104403</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.104403</pub-id><pub-id pub-id-type="pmid">31425750</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juul</surname><given-names>FE</given-names></name><name><surname>Garborg</surname><given-names>K</given-names></name><name><surname>Bretthauer</surname><given-names>M</given-names></name><name><surname>Skudal</surname><given-names>H</given-names></name><name><surname>Oines</surname><given-names>MN</given-names></name><name><surname>Wiig</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Fecal microbiota transplantation for primary clostridium difficile infection</article-title>. <source/>NEJM. (<year>2018</year>) <volume>378</volume>:<fpage>2535</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc1803103</pub-id><pub-id pub-id-type="pmid">29860912</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Clostridium butyricum attenuates cerebral ischemia/reperfusion injury in diabetic mice via modulation of gut microbiota</article-title>. <source/>Brain Res. (<year>2016</year>) <volume>1642</volume>:<fpage>180</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2016.03.042</pub-id><pub-id pub-id-type="pmid">27037183</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MJ</given-names></name><name><surname>Sohrabji</surname><given-names>F</given-names></name></person-group>. <article-title>The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats</article-title>. <source/>J Neuroinflammation. (<year>2016</year>) <volume>13</volume>:<fpage>300</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-016-0765-6</pub-id><pub-id pub-id-type="pmid">27905989</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Leng</surname><given-names>Y</given-names></name><name><surname>Tsai</surname><given-names>LK</given-names></name><name><surname>Leeds</surname><given-names>P</given-names></name><name><surname>Chuang</surname><given-names>DM</given-names></name></person-group>. <article-title>Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of hDAC and mMP-9 inhibition</article-title>. <source/>J Cereb Blood Flow Metab. (<year>2011</year>) <volume>31</volume>:<fpage>52</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2010.195</pub-id><pub-id pub-id-type="pmid">20978517</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>TW</given-names></name><name><surname>Darlington</surname><given-names>LG</given-names></name></person-group>. <article-title>The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders</article-title>. <source/>Br J Pharmacol. (<year>2013</year>) <volume>169</volume>:<fpage>1211</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12230</pub-id><pub-id pub-id-type="pmid">23647169</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Markey</surname><given-names>SP</given-names></name><name><surname>Heyes</surname><given-names>MP</given-names></name></person-group>. <article-title>Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse</article-title>. <source/>Neuroscience. (<year>1992</year>) <volume>51</volume>:<fpage>25</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/0306-4522(92)90467-G</pub-id>
<pub-id pub-id-type="pmid">1465184</pub-id></mixed-citation>
</ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term>AMPs</term>
<def>
<p>antimicrobial peptides</p>
</def>
</def-item>
<def-item>
<term>AIS</term>
<def>
<p>acute ischemic stroke</p>
</def>
</def-item>
<def-item>
<term>CCR</term>
<def>
<p>chemokine receptor</p>
</def>
</def-item>
<def-item>
<term>CD</term>
<def>
<p>cluster of differentiation</p>
</def>
</def-item>
<def-item>
<term>GABA</term>
<def>
<p>gamma-aminobutyric acid</p>
</def>
</def-item>
<def-item>
<term>GALT</term>
<def>
<p>gut-associated lymphoid tissue</p>
</def>
</def-item>
<def-item>
<term>Ig</term>
<def>
<p>immunoglobulin</p>
</def>
</def-item>
<def-item>
<term>IL</term>
<def>
<p>interleukins</p>
</def>
</def-item>
<def-item>
<term>LPS</term>
<def>
<p>lipopolysaccharide</p>
</def>
</def-item>
<def-item>
<term>MCP</term>
<def>
<p>monocyte chemoattractant protein</p>
</def>
</def-item>
<def-item>
<term>MODS</term>
<def>
<p>multiple organ dysfunction syndrome</p>
</def>
</def-item>
<def-item>
<term>MYD</term>
<def>
<p>myeloid differentiation primary response protein</p>
</def>
</def-item>
<def-item>
<term>NAFLD</term>
<def>
<p>non-alcoholic fatty acid disease</p>
</def>
</def-item>
<def-item>
<term>NF-kB</term>
<def>
<p>nuclear factor-kappa B</p>
</def>
</def-item>
<def-item>
<term>NLRs</term>
<def>
<p>nucleotide-binding oligomerization domain-containing protein receptors</p>
</def>
</def-item>
<def-item>
<term>NOD</term>
<def>
<p>nucleotide-binding oligomerization domain-containing protein</p>
</def>
</def-item>
<def-item>
<term>PAMPs</term>
<def>
<p>pathogen associated molecular pattern</p>
</def>
</def-item>
<def-item>
<term>PRRs</term>
<def>
<p>pattern recognition receptor</p>
</def>
</def-item>
<def-item>
<term>RIPK</term>
<def>
<p>receptor-interacting protein kinase</p>
</def>
</def-item>
<def-item>
<term>SDI</term>
<def>
<p>stroke dysbiosis index</p>
</def>
</def-item>
<def-item>
<term>SCFA</term>
<def>
<p>short-chain fatty acid</p>
</def>
</def-item>
<def-item>
<term>TCR</term>
<def>
<p>T cell antigen receptor</p>
</def>
</def-item>
<def-item>
<term>TLRs</term>
<def>
<p>toll-like receptors</p>
</def>
</def-item>
<def-item>
<term>TMAO</term>
<def>
<p>trimethylamine N-oxide</p>
</def>
</def-item>
<def-item>
<term>Treg</term>
<def>
<p>T regulator lymphocytes</p>
</def>
</def-item>
<def-item>
<term>TREM</term>
<def>
<p>triggering receptor expressed on myeloid cells.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>